<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T01:39:39Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10035510" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10035510</identifier>
        <datestamp>2023-03-24</datestamp>
        <setSpec>crc</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Cancer Res Commun</journal-id>
              <journal-id journal-id-type="iso-abbrev">Cancer Res Commun</journal-id>
              <journal-title-group>
                <journal-title>Cancer Research Communications</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2767-9764</issn>
              <publisher>
                <publisher-name>American Association for Cancer Research</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10035510</article-id>
              <article-id pub-id-type="pmcid">PMC10035510</article-id>
              <article-id pub-id-type="pmc-uid">10035510</article-id>
              <article-id pub-id-type="pmid">36968138</article-id>
              <article-id pub-id-type="publisher-id">CRC-22-0436</article-id>
              <article-id pub-id-type="doi">10.1158/2767-9764.CRC-22-0436</article-id>
              <article-version id="ver1" article-version-type="VoR">Version of Record</article-version>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Research Article</subject>
                </subj-group>
                <subj-group subj-group-type="category">
                  <subject>CNS Cancers</subject>
                  <subj-group subj-group-type="category">
                    <subject>Gliomas, Glioblastomas</subject>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="category">
                  <subject>Dna Damage And Repair</subject>
                  <subj-group subj-group-type="category">
                    <subject>DNA repair</subject>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="category">
                  <subject>Clinical Trial Results</subject>
                  <subj-group subj-group-type="category">
                    <subject>Phase II clinical trials</subject>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent <italic toggle="yes">IDH1-</italic> and <italic toggle="yes">IDH2</italic>-mutant Glioma</article-title>
                <alt-title alt-title-type="short">Phase II Trial of Olaparib in Recurrent <italic toggle="yes">IDH1/2</italic>-mutant Glioma</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes" equal-contrib="yes">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3400-7211</contrib-id>
                  <name>
                    <surname>Fanucci</surname>
                    <given-names>Kristina</given-names>
                  </name>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing - original draft</role>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing - review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing - review and editing</role>
                  <xref rid="aff1" ref-type="aff">1</xref>
                  <xref rid="afn1" ref-type="author-notes"/>
                  <xref rid="cor1" ref-type="corresp"/>
                </contrib>
                <contrib contrib-type="author" equal-contrib="yes">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8854-1543</contrib-id>
                  <name>
                    <surname>Pilat</surname>
                    <given-names>Mary Jo</given-names>
                  </name>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing - original draft</role>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing - review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing - review and editing</role>
                  <xref rid="aff2" ref-type="aff">2</xref>
                  <xref rid="afn1" ref-type="author-notes"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2345-3390</contrib-id>
                  <name>
                    <surname>Shyr</surname>
                    <given-names>Derek</given-names>
                  </name>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing - review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing - review and editing</role>
                  <xref rid="aff3" ref-type="aff">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2086-9670</contrib-id>
                  <name>
                    <surname>Shyr</surname>
                    <given-names>Yu</given-names>
                  </name>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing - review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing - review and editing</role>
                  <xref rid="aff4" ref-type="aff">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-1388-9665</contrib-id>
                  <name>
                    <surname>Boerner</surname>
                    <given-names>Scott</given-names>
                  </name>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing - review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing - review and editing</role>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9924-1386</contrib-id>
                  <name>
                    <surname>Li</surname>
                    <given-names>Jing</given-names>
                  </name>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing - review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing - review and editing</role>
                  <xref rid="aff1" ref-type="aff">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6486-556X</contrib-id>
                  <name>
                    <surname>Durecki</surname>
                    <given-names>Diane</given-names>
                  </name>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing - review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing - review and editing</role>
                  <xref rid="aff5" ref-type="aff">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8187-7119</contrib-id>
                  <name>
                    <surname>Drappatz</surname>
                    <given-names>Jan</given-names>
                  </name>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing - review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing - review and editing</role>
                  <xref rid="aff6" ref-type="aff">6</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8396-9500</contrib-id>
                  <name>
                    <surname>Puduvalli</surname>
                    <given-names>Vinay</given-names>
                  </name>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing - review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing - review and editing</role>
                  <xref rid="aff7" ref-type="aff">7</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2577-3336</contrib-id>
                  <name>
                    <surname>Lieberman</surname>
                    <given-names>Frank Scott</given-names>
                  </name>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing - review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing - review and editing</role>
                  <xref rid="aff6" ref-type="aff">6</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2060-7902</contrib-id>
                  <name>
                    <surname>Gonzalez</surname>
                    <given-names>Javier</given-names>
                  </name>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing - review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing - review and editing</role>
                  <xref rid="aff7" ref-type="aff">7</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5165-0984</contrib-id>
                  <name>
                    <surname>Giglio</surname>
                    <given-names>Pierre</given-names>
                  </name>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing - review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing - review and editing</role>
                  <xref rid="aff7" ref-type="aff">7</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7747-072X</contrib-id>
                  <name>
                    <surname>Ivy</surname>
                    <given-names>S. Percy</given-names>
                  </name>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing - review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing - review and editing</role>
                  <xref rid="aff8" ref-type="aff">8</xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3255-0467</contrib-id>
                  <name>
                    <surname>Bindra</surname>
                    <given-names>Ranjit S.</given-names>
                  </name>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing - original draft</role>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing - review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing - review and editing</role>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib contrib-type="author" equal-contrib="yes">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4299-3664</contrib-id>
                  <name>
                    <surname>Omuro</surname>
                    <given-names>Antonio</given-names>
                  </name>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing - original draft</role>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing - review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing - review and editing</role>
                  <xref rid="aff1" ref-type="aff">1</xref>
                  <xref rid="afn1" ref-type="author-notes"/>
                </contrib>
                <contrib contrib-type="author" equal-contrib="yes">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7144-036X</contrib-id>
                  <name>
                    <surname>LoRusso</surname>
                    <given-names>Patricia</given-names>
                  </name>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing - original draft</role>
                  <role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing - review and editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing - review and editing</role>
                  <xref rid="aff1" ref-type="aff">1</xref>
                  <xref rid="afn1" ref-type="author-notes"/>
                </contrib>
              </contrib-group>
              <aff id="aff1"><label>1</label>Yale Cancer Center, New Haven, Connecticut.</aff>
              <aff id="aff2"><label>2</label>Wayne State University, Detroit, Michigan.</aff>
              <aff id="aff3"><label>3</label>Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.</aff>
              <aff id="aff4"><label>4</label>Department of Biomedical Informatics, Vanderbilt University, Nashville, Tennessee.</aff>
              <aff id="aff5"><label>5</label>University of Michigan Medical Center, Ann Arbor, Michigan.</aff>
              <aff id="aff6"><label>6</label>University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania.</aff>
              <aff id="aff7"><label>7</label>Division of Neuro-Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio.</aff>
              <aff id="aff8"><label>8</label>NCI, Bethesda, Maryland.</aff>
              <author-notes>
                <fn fn-type="equal" id="afn1">
                  <p>K. Fanucci and M.J. Pilat contributed as co-first authors and A. Omuro and P. LoRusso as co-last authors to this article.</p>
                </fn>
                <fn fn-type="other" id="afn2">
                  <p>Prior presentation: This study was presented at ASCO 2022 Abstract #367158.</p>
                </fn>
                <corresp id="cor1"><bold>Corresponding Author:</bold> Kristina Fanucci, Yale University, New Haven, CT 06510. Phone: 203-785-4095; E-mail: <email>Kristina.fanucci@yale.edu</email></corresp>
              </author-notes>
              <pub-date pub-type="collection" iso-8601-date="2023-02-02">
                <month>2</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="epub" iso-8601-date="2023-02-02">
                <day>02</day>
                <month>2</month>
                <year>2023</year>
              </pub-date>
              <volume>3</volume>
              <issue>2</issue>
              <fpage>192</fpage>
              <lpage>201</lpage>
              <history>
                <date date-type="received">
                  <day>26</day>
                  <month>10</month>
                  <year>2022</year>
                </date>
                <date date-type="rev-recd">
                  <day>21</day>
                  <month>12</month>
                  <year>2022</year>
                </date>
                <date date-type="accepted">
                  <day>19</day>
                  <month>1</month>
                  <year>2023</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© 2023 The Authors; Published by the American Association for Cancer Research</copyright-statement>
                <copyright-year>2023</copyright-year>
                <copyright-holder>Copyright held by the owner/author(s).</copyright-holder>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license.</license-p>
                </license>
              </permissions>
              <self-uri xlink:href="crc-22-0436.pdf"/>
              <abstract>
                <sec>
                  <title>Purpose:</title>
                  <p>Isocitrate dehydrogenase (<italic toggle="yes">IDH</italic>) <italic toggle="yes">1</italic> and <italic toggle="yes">IDH2</italic> mutations (<italic toggle="yes">IDH1/2</italic>mt) are frequent in glioma. Preclinical studies suggest <italic toggle="yes">IDH1/2</italic>mts confer “BRCAness” phenotype, a vulnerability that can be targeted through PARP inhibition. To test this hypothesis, we conducted a multicenter study of olaparib monotherapy in patients with <italic toggle="yes">IDH1/2</italic>mt gliomas.</p>
                </sec>
                <sec>
                  <title>Methods:</title>
                  <p>Patients with recurrent, contrast-enhancing <italic toggle="yes">IDH1/2</italic>mt gliomas were enrolled in a two-step phase II trial; the primary endpoint was overall response rate per Response Assessment in Neuro-Oncology (RANO) criteria. Olaparib 300 mg orally twice daily was given.</p>
                </sec>
                <sec>
                  <title>Results:</title>
                  <p>A total of 15 evaluable patients were enrolled. Histology was astrocytoma (<italic toggle="yes">N</italic> = 12) and oligodendroglioma (<italic toggle="yes">N</italic> = 3). Most toxicities were grade 1 or 2. Best response was stable disease (SD) in 9 (60%) patients. Median progression-free survival (PFS) was 3.63 months and median overall survival was 20.7 months. For patients with SD, median PFS was 5.53 months; 4 patients had SD for &gt;6 months. Among patients with best response progressive disease (<italic toggle="yes">N</italic> = 6), 5 had grade 4 tumor and 4 had known <italic toggle="yes">CDKN2A</italic> alteration. PFS was 5.23 months for grades 2 or 3 tumors (<italic toggle="yes">N</italic> = 10) versus 1.8 months for grade 4 (<italic toggle="yes">N</italic> = 5; <italic toggle="yes">P</italic> = 0.0013).</p>
                </sec>
                <sec>
                  <title>Conclusion:</title>
                  <p>The study did not meet the prespecified response-based activity threshold for moving to step 2. However, prolonged SD was observed in patients with grades 2 and 3 histologies, suggesting olaparib monotherapy could be of clinical benefit in select populations. Grade 4 tumors per 2021 World Health Organization classification defined by histology or <italic toggle="yes">CDKN2A</italic> alteration derived no benefit from this drug, highlighting the usefulness of this classification for future patient stratification and trial design.</p>
                </sec>
                <sec>
                  <title>Significance:</title>
                  <p>A single-arm phase II trial of olaparib in <italic toggle="yes">IDH</italic>-mutant glioma demonstrated clinically significant prolonged SD for select patients with grade 2/3 disease, suggesting potential benefit of olaparib in <italic toggle="yes">IDH</italic>-mutant gliomas.</p>
                </sec>
              </abstract>
              <funding-group>
                <award-group id="funding-1">
                  <funding-source>
                    <institution-wrap>
                      <institution-id>http://dx.doi.org/10.13039/501100016982</institution-id>
                      <institution>Rising Tide Foundation (RTF)</institution>
                    </institution-wrap>
                  </funding-source>
                  <principal-award-recipient>
                    <name>
                      <surname>LoRusso</surname>
                      <given-names>Patricia</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="funding-2">
                  <funding-source>
                    <institution-wrap>
                      <institution-id>http://dx.doi.org/10.13039/100008222</institution-id>
                      <institution>Ben and Catherine Ivy Foundation (BCIF)</institution>
                    </institution-wrap>
                  </funding-source>
                  <principal-award-recipient>
                    <name>
                      <surname>LoRusso</surname>
                      <given-names>Patricia</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <award-group id="funding-3">
                  <funding-source>
                    <institution-wrap>
                      <institution>CTEP</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>1UM1CA186689</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>LoRusso</surname>
                      <given-names>Patricia</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
              </funding-group>
              <counts>
                <page-count count="10"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>crossmark</meta-name>
                  <meta-value>true</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec sec-type="intro" id="sec1">
              <title>Introduction</title>
              <p>Gliomas represent a heterogenous group of diseases that account for most primary brain tumors (<xref rid="bib1" ref-type="bibr">1</xref>). The discovery of isocitrate dehydrogenase <italic toggle="yes">(IDH</italic>) <italic toggle="yes">1</italic> and <italic toggle="yes">IDH2</italic> mutations (<italic toggle="yes">IDH1/2</italic>mt) in a subset of adult-type diffuse gliomas (<xref rid="bib2" ref-type="bibr">2</xref>) and the observed improved prognosis associated with this phenotype (<xref rid="bib3" ref-type="bibr">3</xref>) have led to the incorporation of this disease-defining molecular feature into the World Health Organization (WHO) classification of brain tumors (<xref rid="bib4" ref-type="bibr">4</xref>). <italic toggle="yes">IDH1</italic>mts occur in more than 70% of what was formerly termed “low-grade” gliomas and up to 20% of “higher-grade” tumors; <italic toggle="yes">IDH2</italic> mutations have been found in about 4% of gliomas (<xref rid="bib2" ref-type="bibr">2</xref>). Bai and colleagues demonstrated that in gliomas, the <italic toggle="yes">IDH1</italic>mts initially present at diagnosis persist if the tumor recurs (<xref rid="bib5" ref-type="bibr">5</xref>). The 2021 WHO classification of brain tumors now divides <italic toggle="yes">IDH</italic>mt tumors into oligodendrogliomas, which harbor a 1p/19q codeletion, and astrocytomas, typically characterized by <italic toggle="yes">ATRX</italic> mutations (<xref rid="bib6" ref-type="bibr">6</xref>). On the basis of histologic features and expected prognosis, oligodendrogliomas can be further graded into WHO grades 2 and 3, and astrocytomas into WHO grades 2 to 4. <italic toggle="yes">IDH</italic>mt astrocytomas with <italic toggle="yes">CDKN2A/B</italic> homozygous deletion are graded as 4 regardless of histology. <italic toggle="yes">IDH</italic>mt gliomas with grade 4 histologic features are no longer termed glioblastoma, given the distinct biology and prognosis.</p>
              <p>In general, first-line treatment for gliomas includes maximal safe resection which is often limited by tumor extent and location, adjuvant radiation, and alkylator-based chemotherapy. Chemotherapy options include temozolomide or combination of procarbazine, lomustine, and vincristine (<xref rid="bib7" ref-type="bibr">7–11</xref>). While a better prognosis is observed in oligodendrogliomas, the disease invariably recurs. Hence novel therapy options are clearly needed.</p>
              <p>In addition to its prognostic significance, <italic toggle="yes">IDH1/2</italic>mt is also a promising therapeutic target in the treatment of glioma. The normal function of <italic toggle="yes">IDH</italic> is to catalyze conversion of isocitrate to alpha-ketoglutarate in the citric acid cycle (<xref rid="bib12" ref-type="bibr">12</xref>). <italic toggle="yes">IDH1/2</italic>mts induce aberrant formation of the oncometabolite 2-hydroxyglutarate (2HG), which is implicated in cancer progression through its inhibitory effect on alpha-ketoglutarate–dependent dioxygenases (<xref rid="bib13" ref-type="bibr">13, 14</xref>). <italic toggle="yes">IDH</italic> has been successfully targeted in other malignancies that carry <italic toggle="yes">IDH</italic>mt. Currently, two drugs have been approved by the FDA: ivosidenib, approved for <italic toggle="yes">IDH1</italic>mt acute myeloid leukemia (AML) and cholangiocarcinoma, and enasidenib, approved in <italic toggle="yes">IDH2</italic>mt AML (<xref rid="bib15" ref-type="bibr">15–17</xref>). Trials investigating ivosidenib and vorasidenib in <italic toggle="yes">IDH</italic>mt gliomas have been published recently (<xref rid="bib18" ref-type="bibr">18, 19</xref>) and are also ongoing (<xref rid="bib20" ref-type="bibr">20, 21</xref>).</p>
              <p>Preclinically, <italic toggle="yes">IDH1/2</italic>mts induce a homologous recombination defect which renders tumor cells sensitive to PARP inhibitors (PARPi; ref. <xref rid="bib22" ref-type="bibr">22</xref>). This “BRCAness” phenotype, with sensitivity to PARPi, is due to a single alpha-ketoglutarate–dependent dioxygenase targeted by 2HG, KDM4A, which mediates homologous recombination (<xref rid="bib22" ref-type="bibr">22</xref>). <italic toggle="yes">IDH1</italic>-dependent PARPi sensitivity has been shown in culture in patient-derived glioma cells as well as genetically matched tumor xenografts <italic toggle="yes">in vivo</italic> (<xref rid="bib22" ref-type="bibr">22</xref>). This “BRCAness” was significant in <italic toggle="yes">IDH1/2</italic>mt cells and approached a 50-fold difference compared with <italic toggle="yes">IDH1</italic> wildtype cells when exposed to olaparib (<xref rid="bib22" ref-type="bibr">22</xref>). Olaparib, an orally bioavailable PARPi, has central nervous system (CNS) penetrance (<xref rid="bib23" ref-type="bibr">23, 24</xref>) and is currently FDA approved for the treatment of several BRCA-mutated tumors (<xref rid="bib25" ref-type="bibr">25</xref>). We report the results of a multicenter prospective phase II study investigating the role of olaparib monotherapy in recurrent or progressive <italic toggle="yes">IDH1/2</italic>mt gliomas.</p>
            </sec>
            <sec sec-type="methods" id="sec2">
              <title>Materials and Methods</title>
              <sec id="sec2-1">
                <title>Patient Selection</title>
                <p>Eligible patients had recurrent or transformed glioma that progressed despite standard therapy or for which no effective standard therapy existed with evidence of an <italic toggle="yes">IDH1/2</italic>mt associated with neomorphic activity of encoded proteins. On the basis of archived histology, tumors of all grades were eligible, but the presence of tumor contrast enhancement on T1 post-gadolinium MRIs performed prior to enrollment was required for all patients, as a surrogate marker of progression to a high-grade histology. Specific criteria for patient eligibility, tumor classification, and progression (<xref rid="bib4" ref-type="bibr">4</xref>) can be found in <xref rid="SMD1" ref-type="supplementary-material">Supplementary Data S1</xref>. The representativeness of study participants is discussed in <xref rid="SMT1" ref-type="supplementary-material">Supplementary Table S1</xref>.</p>
              </sec>
              <sec id="sec2-2">
                <title>Study Treatment and Design</title>
                <p>The primary objective of this trial was to estimate the overall response rate (ORR) of olaparib in patients with <italic toggle="yes">IDH</italic> inhibitor naïve <italic toggle="yes">IDH1/2</italic>mt glioma. Secondary objectives were to estimate the distribution of progression-free survival (PFS), the overall survival (OS) and the duration of response in this population. Safety and tolerability of olaparib were also evaluated.</p>
                <p>Treatment cycles were 28 days. Patients were administered olaparib in tablet form orally 300 mg twice daily continually, irrespective of food intake. No premedications were required. Toxicities were graded using the NCI Common Terminology Criteria for Adverse Events version 5.0. Retreatment criteria can be found in <xref rid="SMD1" ref-type="supplementary-material">Supplementary Data S2</xref>. Patients were monitored for disease status using Response Assessment in Neuro-Oncology (RANO) criteria with MRI performed every 8 weeks. Because of preliminary findings suggesting prolonged stable disease (SD) in some patients, an independent review was commissioned. Results were compared with those reported by local investigator. Any discordance was reported and investigated.</p>
                <p>Written informed consent was obtained from enrolled patients. Institutional Review Board approvals of the protocol and consent forms were obtained from all sites. Protocol design and conduct complied with all applicable regulations, guidance, and local policies. The study was conducted in accordance with the Declaration of Helsinki. The trial was conducted under an NCI-sponsored Investigational New Drug application (<ext-link xlink:href="www.ClinicalTrials.gov:" ext-link-type="uri" xlink:show="new">www.ClinicalTrials.gov:</ext-link> NCT03212274). Olaparib was supplied by the Division of Cancer Treatment and Diagnosis of the NCI.</p>
              </sec>
              <sec sec-type="methods" id="sec2-3">
                <title>Statistical Methods</title>
                <p>The power analysis and sample size estimation were completed using the Bayesian adaptive trial design method. We modeled the probability of ORR using Beta distributions. The prior distribution is Beta(0.1, 0.9), which is fairly pessimistic; the expected value is 0.1, reflecting the response rate based on previous experiences. We estimated the ORR using the posterior distribution and reported its median and 90% credible interval (see protocol for details). It was predetermined that the trial would be terminated if there was a lack of response, that is, the probability of the ORR being greater than 0.1 was 50% or less. Because the ORR in the trial was zero, the trial was terminated. The SD rate and the progressive disease (PD) rate were reported, and the 90% credible intervals were estimated using the posterior distribution. SD was defined as lack of progression at first restaging after two cycles.</p>
                <p>For secondary objectives, the median PFS and OS were estimated using Kaplan–Meier estimate with 95% confidence intervals (CI). The CIs were based on Greenwood formula for variance. Possible risk factors for PFS and OS of WHO grade and <italic toggle="yes">CDKN2A</italic> alteration were compared using the log-rank test. For the secondary objectives, all tests were two sided. Statistical analyses were performed using the R 4.1.1 software.</p>
              </sec>
              <sec sec-type="data-availability" id="sec2-4">
                <title>Data Availability</title>
                <p>The data generated in this study are available upon request from the corresponding author.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="sec3">
              <title>Results</title>
              <sec id="sec3-1">
                <title>Patient Demographics</title>
                <p>Sixteen patients were enrolled. Fifteen patients were evaluable for response and toxicity. One patient was found to be ineligible after signing consent (<xref rid="fig1" ref-type="fig">Fig. 1</xref>). Gliomas were further divided according to WHO 2021 grading system by the following subtypes: grades 2 and 3 astrocytomas (n = 7), grade 4 astrocytoma, formerly known as gliblastoma (n = 5), and grades 2 and 3 oligodendrogliomas (n = 3) (<xref rid="tbl1" ref-type="table">Table 1</xref>). <italic toggle="yes">IDH</italic>mt was confirmed for each patient, either through prior documentation or testing during enrollment period. Tumors from 13 of 15 patients were found to have mutations that led to the R132H neomorphic phenotype in the <italic toggle="yes">IDH1</italic> gene (one tumor also contained a variant mutation of uncertain significance in <italic toggle="yes">IDH2</italic>) and 2 of 15 patients had tumors which harbored neomorphic mutations in the <italic toggle="yes">IDH2</italic> gene (R172G and R172K; <xref rid="tbl2" ref-type="table">Table 2</xref>). <italic toggle="yes">CDKN2A</italic> copy-number loss was documented in 5 patients (<xref rid="tbl2" ref-type="table">Table 2</xref>). Patient demographics and prior treatments are summarized in <xref rid="tbl1" ref-type="table">Table 1</xref>. All patients had evidence of progression at enrollment.</p>
                <fig position="float" id="fig1">
                  <label>FIGURE 1</label>
                  <caption>
                    <p>Consort diagram.</p>
                  </caption>
                  <graphic xlink:href="crc-22-0436_fig1" position="float"/>
                </fig>
                <table-wrap position="float" id="tbl1">
                  <label>TABLE 1</label>
                  <caption>
                    <p>Demographics and baseline characteristics (<italic toggle="yes">n</italic> = 15)</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                    </colgroup>
                    <tbody>
                      <tr>
                        <td colspan="2" align="left" rowspan="1">
                          <bold>Demographics</bold>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Gender<break/> Male<break/> Female</td>
                        <td align="left" rowspan="1" colspan="1"><break/>10<break/>5</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Median (range) age in years</td>
                        <td align="left" rowspan="1" colspan="1">38 (23–69)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Race<break/> Caucasian<break/> Black</td>
                        <td align="left" rowspan="1" colspan="1"><break/>14<break/>1</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Performance status<break/> 0<break/> 1<break/> 2</td>
                        <td align="left" rowspan="1" colspan="1"><break/>5<break/>9<break/>1</td>
                      </tr>
                      <tr>
                        <td colspan="2" align="left" rowspan="1">
                          <bold>Original histology</bold>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Astrocytoma<break/> WHO 2016 grade 2<break/> WHO 2016 grade 3</td>
                        <td align="left" rowspan="1" colspan="1"><break/>4<break/>5</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Glioblastoma<break/> WHO 2016 grade 4</td>
                        <td align="left" rowspan="1" colspan="1"><break/>3</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Oligodendroglioma<break/> WHO 2016 grade 2<break/> WHO 2016 grade 3</td>
                        <td align="left" rowspan="1" colspan="1"><break/>2<break/>1</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">IDH mutation status<break/> IDH1<break/> IDH2</td>
                        <td align="left" rowspan="1" colspan="1"><break/>13<break/>2</td>
                      </tr>
                      <tr>
                        <td colspan="2" align="left" rowspan="1">
                          <bold>WHO 2021 grading</bold>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Astrocytoma<break/> WHO 2021 grade 2<break/> WHO 2021 grade 3<break/> WHO 2021 grade 4</td>
                        <td align="left" rowspan="1" colspan="1"><break/>4<break/>3<break/>5</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Oligodendroglioma<break/> WHO 2021 grade 2<break/> WHO 2021 grade 3</td>
                        <td align="left" rowspan="1" colspan="1"><break/>2<break/>1</td>
                      </tr>
                      <tr>
                        <td colspan="2" align="left" rowspan="1">
                          <bold>Prior treatment</bold>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Surgery<break/> Surgical resection<break/> Biopsy</td>
                        <td align="left" rowspan="1" colspan="1"><break/>11<break/>4</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Radiation<break/> Yes<break/> No<break/>Median (range) time in years from last radiation to olaparib initiation</td>
                        <td align="left" rowspan="1" colspan="1"><break/>14<break/>1<break/>15.48 (0.59–10.59)</td>
                      </tr>
                      <tr>
                        <td colspan="2" align="left" rowspan="1">
                          <bold>Prior chemotherapy</bold>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Temozolomide<break/> Adjuvant<break/> Neoadjuvant</td>
                        <td align="left" rowspan="1" colspan="1">13<break/>10<break/>9</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Procarbazine/Vincrinstine/Lomustine<break/> Adjuvant<break/> Neoadjuvant<break/>Bevacizumab<break/>Procarbazine/Lomustine<break/>Temozolomide/Bevacizumab/Lomustine<break/>Carboplatin/Etoposide</td>
                        <td align="left" rowspan="1" colspan="1">3<break/>1<break/>2<break/>2<break/>1<break/>1<break/>1</td>
                      </tr>
                      <tr>
                        <td colspan="2" align="left" rowspan="1">
                          <bold>Prior immunotherapy</bold>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Nivolumab</td>
                        <td align="left" rowspan="1" colspan="1">2</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1"><bold>Prior lines of chemotherapy/immunotherapy</bold><break/> 1<break/> 2<break/> 3<break/> 4</td>
                        <td align="left" rowspan="1" colspan="1"><break/>5<break/>5<break/>3<break/>2</td>
                      </tr>
                    </tbody>
                  </table>
                </table-wrap>
                <table-wrap position="float" id="tbl2">
                  <label>TABLE 2</label>
                  <caption>
                    <p>Summary of patients’ diagnosis and tumor characteristics</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th align="left" rowspan="1" colspan="1">Patient</th>
                        <th align="left" rowspan="1" colspan="1">Original histology report</th>
                        <th align="left" rowspan="1" colspan="1">Original histologic grading</th>
                        <th align="left" rowspan="1" colspan="1">Grading by 2021 WHO classification</th>
                        <th align="left" rowspan="1" colspan="1">Date of diagnosis</th>
                        <th align="left" rowspan="1" colspan="1">Surgery</th>
                        <th align="left" rowspan="1" colspan="1">Radiotherapy</th>
                        <th align="left" rowspan="1" colspan="1">Adjuvant therapy</th>
                        <th align="left" rowspan="1" colspan="1">Number of prior treatments</th>
                        <th align="left" rowspan="1" colspan="1">IDH mutation</th>
                        <th align="left" rowspan="1" colspan="1">CDKN2A alteration</th>
                        <th align="left" rowspan="1" colspan="1">ATRX mutation</th>
                        <th align="left" rowspan="1" colspan="1">MGMT promotor methylation</th>
                        <th align="left" rowspan="1" colspan="1">Other alterations/Comments</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">1</td>
                        <td align="left" rowspan="1" colspan="1">Anaplastic Astrocytoma</td>
                        <td align="left" rowspan="1" colspan="1">3</td>
                        <td align="left" rowspan="1" colspan="1">3</td>
                        <td align="left" rowspan="1" colspan="1">5/2010</td>
                        <td align="left" rowspan="1" colspan="1">Y</td>
                        <td align="left" rowspan="1" colspan="1">Y</td>
                        <td align="left" rowspan="1" colspan="1">Y</td>
                        <td align="left" rowspan="1" colspan="1">3</td>
                        <td align="left" rowspan="1" colspan="1">IDH1 R132H</td>
                        <td align="left" rowspan="1" colspan="1">ND</td>
                        <td align="left" rowspan="1" colspan="1">E1522*</td>
                        <td align="left" rowspan="1" colspan="1">Y</td>
                        <td align="left" rowspan="1" colspan="1">mTP53; TMB low; MS stable; PD-L1&lt;1%; EGFR amplification-ND</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">2</td>
                        <td align="left" rowspan="1" colspan="1">Anaplastic Astrocytoma</td>
                        <td align="left" rowspan="1" colspan="1">3</td>
                        <td align="left" rowspan="1" colspan="1">4</td>
                        <td align="left" rowspan="1" colspan="1">1/2011</td>
                        <td align="left" rowspan="1" colspan="1">Y</td>
                        <td align="left" rowspan="1" colspan="1">Y</td>
                        <td align="left" rowspan="1" colspan="1">Y</td>
                        <td align="left" rowspan="1" colspan="1">3</td>
                        <td align="left" rowspan="1" colspan="1">IDH1 R132H</td>
                        <td align="left" rowspan="1" colspan="1">CNL</td>
                        <td align="left" rowspan="1" colspan="1">p.K329lfs*3</td>
                        <td align="left" rowspan="1" colspan="1">Y</td>
                        <td align="left" rowspan="1" colspan="1">mTP53; CIC-CNL</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">3</td>
                        <td align="left" rowspan="1" colspan="1">Low grade astrocytoma/glioma</td>
                        <td align="left" rowspan="1" colspan="1">2</td>
                        <td align="left" rowspan="1" colspan="1">2</td>
                        <td align="left" rowspan="1" colspan="1">12/2014</td>
                        <td align="left" rowspan="1" colspan="1">Biopsy only</td>
                        <td align="left" rowspan="1" colspan="1">Y</td>
                        <td align="left" rowspan="1" colspan="1">Y</td>
                        <td align="left" rowspan="1" colspan="1">3</td>
                        <td align="left" rowspan="1" colspan="1">IDH2 R172G</td>
                        <td align="left" rowspan="1" colspan="1">ND</td>
                        <td align="left" rowspan="1" colspan="1">Q468fs*4</td>
                        <td align="left" rowspan="1" colspan="1">NR</td>
                        <td align="left" rowspan="1" colspan="1">mTP53; mCHEK2; TMB low; MS stable</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">4</td>
                        <td align="left" rowspan="1" colspan="1">Infiltrating glioma with astrocytic phenotype</td>
                        <td align="left" rowspan="1" colspan="1">3</td>
                        <td align="left" rowspan="1" colspan="1">4</td>
                        <td align="left" rowspan="1" colspan="1">4/2015</td>
                        <td align="left" rowspan="1" colspan="1">Y</td>
                        <td align="left" rowspan="1" colspan="1">Y</td>
                        <td align="left" rowspan="1" colspan="1">Y</td>
                        <td align="left" rowspan="1" colspan="1">1</td>
                        <td align="left" rowspan="1" colspan="1">IDH1 R132H</td>
                        <td align="left" rowspan="1" colspan="1">CNL</td>
                        <td align="left" rowspan="1" colspan="1">LON<sup>i</sup></td>
                        <td align="left" rowspan="1" colspan="1">Y</td>
                        <td align="left" rowspan="1" colspan="1">1 q status conserved; 19 q status conserved; mTP53; PTEN-CNL<break/>Low level amplification of MYC and MYCN</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">5</td>
                        <td align="left" rowspan="1" colspan="1">Anaplastic Astrocytoma</td>
                        <td align="left" rowspan="1" colspan="1">3</td>
                        <td align="left" rowspan="1" colspan="1">3</td>
                        <td align="left" rowspan="1" colspan="1">3/2012</td>
                        <td align="left" rowspan="1" colspan="1">Biopsy only</td>
                        <td align="left" rowspan="1" colspan="1">Y</td>
                        <td align="left" rowspan="1" colspan="1">Y</td>
                        <td align="left" rowspan="1" colspan="1">4</td>
                        <td align="left" rowspan="1" colspan="1">IDH1 R132H</td>
                        <td align="left" rowspan="1" colspan="1">ND</td>
                        <td align="left" rowspan="1" colspan="1">NR</td>
                        <td align="left" rowspan="1" colspan="1">Y</td>
                        <td align="left" rowspan="1" colspan="1">mTP53; EGFR amplification-ND<break/>1 q status conserved; 19 q status conserved; PTEN-33% loss; Chromosome 17p-100% loss</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">6</td>
                        <td align="left" rowspan="1" colspan="1">Infiltrating Astrocytoma</td>
                        <td align="left" rowspan="1" colspan="1">2</td>
                        <td align="left" rowspan="1" colspan="1">2</td>
                        <td align="left" rowspan="1" colspan="1">9/2012</td>
                        <td align="left" rowspan="1" colspan="1">Biopsy only</td>
                        <td align="left" rowspan="1" colspan="1">Y</td>
                        <td align="left" rowspan="1" colspan="1">N</td>
                        <td align="left" rowspan="1" colspan="1">1</td>
                        <td align="left" rowspan="1" colspan="1">IDH1 R132H</td>
                        <td align="left" rowspan="1" colspan="1">ND</td>
                        <td align="left" rowspan="1" colspan="1">NR</td>
                        <td align="left" rowspan="1" colspan="1">Y</td>
                        <td align="left" rowspan="1" colspan="1">1 q status conserved; 19 q status conserved; p53 positive; EGFR amplification-ND</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">7</td>
                        <td align="left" rowspan="1" colspan="1">Anaplastic oligodendroglioma</td>
                        <td align="left" rowspan="1" colspan="1">3</td>
                        <td align="left" rowspan="1" colspan="1">3</td>
                        <td align="left" rowspan="1" colspan="1">11/2005</td>
                        <td align="left" rowspan="1" colspan="1">Biopsy only</td>
                        <td align="left" rowspan="1" colspan="1">Y</td>
                        <td align="left" rowspan="1" colspan="1">Y</td>
                        <td align="left" rowspan="1" colspan="1">4</td>
                        <td align="left" rowspan="1" colspan="1">IDH1 R132H IDH2 VUS</td>
                        <td align="left" rowspan="1" colspan="1">ND</td>
                        <td align="left" rowspan="1" colspan="1">VUS-pT578i</td>
                        <td align="left" rowspan="1" colspan="1">Y</td>
                        <td align="left" rowspan="1" colspan="1">1p 9q deletion; TP53 deletion<break/>TERT promoter mutation; EGFR positive (no amplification)<break/>CIC-CNL<break/>FUBP1-CNL<break/>VUS-PTCH1, NF2, PI3K</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">8</td>
                        <td align="left" rowspan="1" colspan="1">Diffuse astrocytoma</td>
                        <td align="left" rowspan="1" colspan="1">2</td>
                        <td align="left" rowspan="1" colspan="1">2</td>
                        <td align="left" rowspan="1" colspan="1">7/2012</td>
                        <td align="left" rowspan="1" colspan="1">Y</td>
                        <td align="left" rowspan="1" colspan="1">N</td>
                        <td align="left" rowspan="1" colspan="1">Y</td>
                        <td align="left" rowspan="1" colspan="1">2</td>
                        <td align="left" rowspan="1" colspan="1">IDH1 R132H</td>
                        <td align="left" rowspan="1" colspan="1">ND</td>
                        <td align="left" rowspan="1" colspan="1">NR</td>
                        <td align="left" rowspan="1" colspan="1">Y</td>
                        <td align="left" rowspan="1" colspan="1">EGFR positive (no amplification); 1 p, 19q, p16, PTEN all conserved; TP53 deletion positive</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">9</td>
                        <td align="left" rowspan="1" colspan="1">Glioblastoma</td>
                        <td align="left" rowspan="1" colspan="1">4</td>
                        <td align="left" rowspan="1" colspan="1">4</td>
                        <td align="left" rowspan="1" colspan="1">12/2016</td>
                        <td align="left" rowspan="1" colspan="1">Y</td>
                        <td align="left" rowspan="1" colspan="1">Y</td>
                        <td align="left" rowspan="1" colspan="1">Y</td>
                        <td align="left" rowspan="1" colspan="1">1</td>
                        <td align="left" rowspan="1" colspan="1">IDH1 R132H</td>
                        <td align="left" rowspan="1" colspan="1">CNL</td>
                        <td align="left" rowspan="1" colspan="1">Y</td>
                        <td align="left" rowspan="1" colspan="1">N</td>
                        <td align="left" rowspan="1" colspan="1">EGFR-not amplified; 1p and 19q conserved</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">10</td>
                        <td align="left" rowspan="1" colspan="1">Diffuse astrocytoma</td>
                        <td align="left" rowspan="1" colspan="1">2</td>
                        <td align="left" rowspan="1" colspan="1">2</td>
                        <td align="left" rowspan="1" colspan="1">7/2014</td>
                        <td align="left" rowspan="1" colspan="1">Y</td>
                        <td align="left" rowspan="1" colspan="1">Y</td>
                        <td align="left" rowspan="1" colspan="1">Y</td>
                        <td align="left" rowspan="1" colspan="1">1</td>
                        <td align="left" rowspan="1" colspan="1">IDH1 R132H</td>
                        <td align="left" rowspan="1" colspan="1">ND</td>
                        <td align="left" rowspan="1" colspan="1">pR808* (LOF)</td>
                        <td align="left" rowspan="1" colspan="1">Y</td>
                        <td align="left" rowspan="1" colspan="1">mTP53; TMB low; MS stable; PDL-1 low</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">11</td>
                        <td align="left" rowspan="1" colspan="1">Glioblastoma</td>
                        <td align="left" rowspan="1" colspan="1">4</td>
                        <td align="left" rowspan="1" colspan="1">4</td>
                        <td align="left" rowspan="1" colspan="1">6/2008</td>
                        <td align="left" rowspan="1" colspan="1">Y</td>
                        <td align="left" rowspan="1" colspan="1">Y</td>
                        <td align="left" rowspan="1" colspan="1">Y</td>
                        <td align="left" rowspan="1" colspan="1">1</td>
                        <td align="left" rowspan="1" colspan="1">IDH1 R132H</td>
                        <td align="left" rowspan="1" colspan="1">CNL</td>
                        <td align="left" rowspan="1" colspan="1">Y</td>
                        <td align="left" rowspan="1" colspan="1">N</td>
                        <td align="left" rowspan="1" colspan="1">GFAP positive; TP53 positive<break/>EGFR positive<break/>MET amplification</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">12</td>
                        <td align="left" rowspan="1" colspan="1">Anaplastic Astrocytoma</td>
                        <td align="left" rowspan="1" colspan="1">3</td>
                        <td align="left" rowspan="1" colspan="1">3</td>
                        <td align="left" rowspan="1" colspan="1">3/2010</td>
                        <td align="left" rowspan="1" colspan="1">Y</td>
                        <td align="left" rowspan="1" colspan="1">Y</td>
                        <td align="left" rowspan="1" colspan="1">Y</td>
                        <td align="left" rowspan="1" colspan="1">2</td>
                        <td align="left" rowspan="1" colspan="1">IDH2 R172K</td>
                        <td align="left" rowspan="1" colspan="1">NR</td>
                        <td align="left" rowspan="1" colspan="1">NR</td>
                        <td align="left" rowspan="1" colspan="1">N</td>
                        <td align="left" rowspan="1" colspan="1">Polysomies of both chromosome 1 and 19, no losses; No mutation of TERT promoter</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">13</td>
                        <td align="left" rowspan="1" colspan="1">Oligodendroglioma</td>
                        <td align="left" rowspan="1" colspan="1">2</td>
                        <td align="left" rowspan="1" colspan="1">2</td>
                        <td align="left" rowspan="1" colspan="1">2/2008</td>
                        <td align="left" rowspan="1" colspan="1">Y</td>
                        <td align="left" rowspan="1" colspan="1">Y</td>
                        <td align="left" rowspan="1" colspan="1">Y</td>
                        <td align="left" rowspan="1" colspan="1">2</td>
                        <td align="left" rowspan="1" colspan="1">IDH1 R132H</td>
                        <td align="left" rowspan="1" colspan="1">NR</td>
                        <td align="left" rowspan="1" colspan="1">NR</td>
                        <td align="left" rowspan="1" colspan="1">NR</td>
                        <td align="left" rowspan="1" colspan="1">mPI3CA; mTERT promoter; TMB low; MS stable; PDL-1 low</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">14</td>
                        <td align="left" rowspan="1" colspan="1">Oligodendroglioma</td>
                        <td align="left" rowspan="1" colspan="1">2</td>
                        <td align="left" rowspan="1" colspan="1">2</td>
                        <td align="left" rowspan="1" colspan="1">12/2008</td>
                        <td align="left" rowspan="1" colspan="1">Y</td>
                        <td align="left" rowspan="1" colspan="1">Y</td>
                        <td align="left" rowspan="1" colspan="1">Y</td>
                        <td align="left" rowspan="1" colspan="1">2</td>
                        <td align="left" rowspan="1" colspan="1">IDH1 R132H</td>
                        <td align="left" rowspan="1" colspan="1">NR</td>
                        <td align="left" rowspan="1" colspan="1">NR</td>
                        <td align="left" rowspan="1" colspan="1">NR</td>
                        <td align="left" rowspan="1" colspan="1">TMB low; MS stable; mTP53;</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">15</td>
                        <td align="left" rowspan="1" colspan="1">Glioblastoma</td>
                        <td align="left" rowspan="1" colspan="1">4</td>
                        <td align="left" rowspan="1" colspan="1">4</td>
                        <td align="left" rowspan="1" colspan="1">5/2018</td>
                        <td align="left" rowspan="1" colspan="1">Y</td>
                        <td align="left" rowspan="1" colspan="1">Y</td>
                        <td align="left" rowspan="1" colspan="1">Y</td>
                        <td align="left" rowspan="1" colspan="1">2</td>
                        <td align="left" rowspan="1" colspan="1">IDH1 R132H</td>
                        <td align="left" rowspan="1" colspan="1">CNL</td>
                        <td align="left" rowspan="1" colspan="1">p.Q8883Rfs*21 and LON<sup>i</sup></td>
                        <td align="left" rowspan="1" colspan="1">N</td>
                        <td align="left" rowspan="1" colspan="1">mTP53; PtEN-CNL<break/>1 p and 19 q abnormalities</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn>
                      <p>Abbreviations: CNL, copy-number loss; LOF, loss of function; MS, microsatellite stability; N = No; ND, no genetic alteration detected; NR, not reported; TMB, tumor mutational burden; VUS, variant of unknown significance; Y, Yes.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="sec3-2">
                <title>Toxicity</title>
                <p>There were no unexpected toxicities reported and most toxicities were grade 1 or 2. The most common toxicities were nausea (67%) and fatigue (47%; <xref rid="tbl3" ref-type="table">Table 3</xref>). One patient with a history of ulcerative colitis reported grade 3 diarrhea that resulted in a dose reduction to 250 mg twice daily after the second cycle. The patient was taken off study during cycle 5 due to continued drug-related diarrhea. One patient developed grade 3 hypertension that was possibly attributed to olaparib. Onset was after patient stopped treatment at cycle 12 and subsequently improved at follow-up visit. Finally, grade 3 lymphopenia was reported in 1 patient.</p>
                <table-wrap position="float" id="tbl3">
                  <label>TABLE 3</label>
                  <caption>
                    <p>Most common (&gt;10%) treatment-related and grade 1–3 treatment-related adverse events (maximum grade, all cycles; <italic toggle="yes">n</italic> = 15). No grade 4 or 5 events were reported</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th align="left" rowspan="1" colspan="1">Adverse event</th>
                        <th align="left" rowspan="1" colspan="1">Total number of patients with event <italic toggle="yes">N</italic> (%)</th>
                        <th align="left" rowspan="1" colspan="1">Grade 1 (%)</th>
                        <th align="left" rowspan="1" colspan="1">Grade 2 (%)</th>
                        <th align="left" rowspan="1" colspan="1">Grade 3 (%)</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Nausea</td>
                        <td align="left" rowspan="1" colspan="1">10 (67%)</td>
                        <td align="left" rowspan="1" colspan="1">9 (90%)</td>
                        <td align="left" rowspan="1" colspan="1">1 (10%)</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Fatigue</td>
                        <td align="left" rowspan="1" colspan="1">7 (47%)</td>
                        <td align="left" rowspan="1" colspan="1">4 (57%)</td>
                        <td align="left" rowspan="1" colspan="1">3 (43%)</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Anemia</td>
                        <td align="left" rowspan="1" colspan="1">4 (27%)</td>
                        <td align="left" rowspan="1" colspan="1">4 (100%)</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Elevated LDH</td>
                        <td align="left" rowspan="1" colspan="1">4 (27%)</td>
                        <td align="left" rowspan="1" colspan="1">4 (100%)</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Vomiting</td>
                        <td align="left" rowspan="1" colspan="1">4 (27%)</td>
                        <td align="left" rowspan="1" colspan="1">4 (100%)</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Diarrhea</td>
                        <td align="left" rowspan="1" colspan="1">4 (27%)</td>
                        <td align="left" rowspan="1" colspan="1">2 (50%)</td>
                        <td align="left" rowspan="1" colspan="1">1 (25%)</td>
                        <td align="left" rowspan="1" colspan="1">1 (25%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Lymphopenia</td>
                        <td align="left" rowspan="1" colspan="1">3 (20%)</td>
                        <td align="left" rowspan="1" colspan="1">2 (67%)</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                        <td align="left" rowspan="1" colspan="1">1 (33%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Thrombocytopenia</td>
                        <td align="left" rowspan="1" colspan="1">3 (20%)</td>
                        <td align="left" rowspan="1" colspan="1">3 (100%)</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Anorexia</td>
                        <td align="left" rowspan="1" colspan="1">2 (13%)</td>
                        <td align="left" rowspan="1" colspan="1">2 (100%)</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Leukopenia</td>
                        <td align="left" rowspan="1" colspan="1">2 (13%)</td>
                        <td align="left" rowspan="1" colspan="1">2 (100%)</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Neutropenia</td>
                        <td align="left" rowspan="1" colspan="1">2 (13%)</td>
                        <td align="left" rowspan="1" colspan="1">2 (100%)</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Hypertension</td>
                        <td align="left" rowspan="1" colspan="1">1 (7%)</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                        <td align="left" rowspan="1" colspan="1">—</td>
                        <td align="left" rowspan="1" colspan="1">1 (100%)</td>
                      </tr>
                    </tbody>
                  </table>
                </table-wrap>
              </sec>
              <sec id="sec3-3">
                <title>Efficacy</title>
                <p>All 15 patients were evaluable for response (<xref rid="tbl4" ref-type="table">Table 4</xref>). Nine (60%, 90% credible interval: 37–76) patients achieved SD and 6 (40%, 90% credible interval: 19–58) patients progressed. For patients with SD, the median number of progression-free months was 5.53 (range, 2.83–12.13). Four patients had SD for &gt; 6 months (<xref rid="tbl4" ref-type="table">Table 4</xref>). The remaining 6 patients experienced PD after two cycles with a median of 1.82 months on treatment (range, 1.8–1.9).</p>
                <table-wrap position="float" id="tbl4">
                  <label>TABLE 4</label>
                  <caption>
                    <p>Patients’ response to olaparib</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                      <col align="left" span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th align="left" rowspan="1" colspan="1">Patient</th>
                        <th align="left" rowspan="1" colspan="1">Original histology report</th>
                        <th align="left" rowspan="1" colspan="1">2021 WHO classification</th>
                        <th align="left" rowspan="1" colspan="1">Overall best response</th>
                        <th align="left" rowspan="1" colspan="1">Number of cycles completed</th>
                        <th align="left" rowspan="1" colspan="1">Days on treatment</th>
                        <th align="left" rowspan="1" colspan="1">Months on treatment</th>
                        <th align="left" rowspan="1" colspan="1">Progression-free survival (months)</th>
                        <th align="left" rowspan="1" colspan="1">Overall survival (months)</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">1</td>
                        <td align="left" rowspan="1" colspan="1">Anaplastic Astrocytoma</td>
                        <td align="left" rowspan="1" colspan="1">3</td>
                        <td align="left" rowspan="1" colspan="1">SD</td>
                        <td align="left" rowspan="1" colspan="1">10<xref rid="tb4fn1" ref-type="table-fn"><sup>a</sup></xref></td>
                        <td align="left" rowspan="1" colspan="1">278<xref rid="tb4fn1" ref-type="table-fn"><sup>a</sup></xref></td>
                        <td align="left" rowspan="1" colspan="1">9.3</td>
                        <td align="left" rowspan="1" colspan="1">5.5</td>
                        <td align="left" rowspan="1" colspan="1">10.9+</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">2</td>
                        <td align="left" rowspan="1" colspan="1">Anaplastic Astrocytoma</td>
                        <td align="left" rowspan="1" colspan="1">4</td>
                        <td align="left" rowspan="1" colspan="1">PD</td>
                        <td align="left" rowspan="1" colspan="1">2</td>
                        <td align="left" rowspan="1" colspan="1">56</td>
                        <td align="left" rowspan="1" colspan="1">1.9</td>
                        <td align="left" rowspan="1" colspan="1">1.8</td>
                        <td align="left" rowspan="1" colspan="1">9.1</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">3</td>
                        <td align="left" rowspan="1" colspan="1">Low-grade astrocytoma/glioma</td>
                        <td align="left" rowspan="1" colspan="1">2</td>
                        <td align="left" rowspan="1" colspan="1">SD</td>
                        <td align="left" rowspan="1" colspan="1">12</td>
                        <td align="left" rowspan="1" colspan="1">339</td>
                        <td align="left" rowspan="1" colspan="1">11.3</td>
                        <td align="left" rowspan="1" colspan="1">11.3</td>
                        <td align="left" rowspan="1" colspan="1">12.5+</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">4</td>
                        <td align="left" rowspan="1" colspan="1">Infiltrating glioma with astrocytic phenotype</td>
                        <td align="left" rowspan="1" colspan="1">4</td>
                        <td align="left" rowspan="1" colspan="1">PD</td>
                        <td align="left" rowspan="1" colspan="1">2</td>
                        <td align="left" rowspan="1" colspan="1">54</td>
                        <td align="left" rowspan="1" colspan="1">1.8</td>
                        <td align="left" rowspan="1" colspan="1">1.8</td>
                        <td align="left" rowspan="1" colspan="1">13.8</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">5</td>
                        <td align="left" rowspan="1" colspan="1">Anaplastic Astrocytoma</td>
                        <td align="left" rowspan="1" colspan="1">3</td>
                        <td align="left" rowspan="1" colspan="1">PD</td>
                        <td align="left" rowspan="1" colspan="1">2</td>
                        <td align="left" rowspan="1" colspan="1">56</td>
                        <td align="left" rowspan="1" colspan="1">1.9</td>
                        <td align="left" rowspan="1" colspan="1">1.9</td>
                        <td align="left" rowspan="1" colspan="1">32.1+</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">6</td>
                        <td align="left" rowspan="1" colspan="1">Infiltrating Astrocytoma</td>
                        <td align="left" rowspan="1" colspan="1">2</td>
                        <td align="left" rowspan="1" colspan="1">PD</td>
                        <td align="left" rowspan="1" colspan="1">2</td>
                        <td align="left" rowspan="1" colspan="1">55</td>
                        <td align="left" rowspan="1" colspan="1">1.8</td>
                        <td align="left" rowspan="1" colspan="1">1.8</td>
                        <td align="left" rowspan="1" colspan="1">8.3</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">7</td>
                        <td align="left" rowspan="1" colspan="1">Anaplastic oligodendroglioma</td>
                        <td align="left" rowspan="1" colspan="1">3</td>
                        <td align="left" rowspan="1" colspan="1">SD</td>
                        <td align="left" rowspan="1" colspan="1">5</td>
                        <td align="left" rowspan="1" colspan="1">149</td>
                        <td align="left" rowspan="1" colspan="1">5</td>
                        <td align="left" rowspan="1" colspan="1">4.9</td>
                        <td align="left" rowspan="1" colspan="1">31.5+</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">8</td>
                        <td align="left" rowspan="1" colspan="1">Diffuse astrocytoma</td>
                        <td align="left" rowspan="1" colspan="1">2</td>
                        <td align="left" rowspan="1" colspan="1">SD</td>
                        <td align="left" rowspan="1" colspan="1">8</td>
                        <td align="left" rowspan="1" colspan="1">224</td>
                        <td align="left" rowspan="1" colspan="1">7.5</td>
                        <td align="left" rowspan="1" colspan="1">7.4</td>
                        <td align="left" rowspan="1" colspan="1">20.7</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">9</td>
                        <td align="left" rowspan="1" colspan="1">Glioblastoma</td>
                        <td align="left" rowspan="1" colspan="1">4</td>
                        <td align="left" rowspan="1" colspan="1">SD</td>
                        <td align="left" rowspan="1" colspan="1">4</td>
                        <td align="left" rowspan="1" colspan="1">105</td>
                        <td align="left" rowspan="1" colspan="1">3.5</td>
                        <td align="left" rowspan="1" colspan="1">2.8</td>
                        <td align="left" rowspan="1" colspan="1">16.6</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">10</td>
                        <td align="left" rowspan="1" colspan="1">Diffuse astrocytoma</td>
                        <td align="left" rowspan="1" colspan="1">2</td>
                        <td align="left" rowspan="1" colspan="1">SD</td>
                        <td align="left" rowspan="1" colspan="1">14</td>
                        <td align="left" rowspan="1" colspan="1">364</td>
                        <td align="left" rowspan="1" colspan="1">12.1</td>
                        <td align="left" rowspan="1" colspan="1">12.1</td>
                        <td align="left" rowspan="1" colspan="1">29.5</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">11</td>
                        <td align="left" rowspan="1" colspan="1">Glioblastoma</td>
                        <td align="left" rowspan="1" colspan="1">4</td>
                        <td align="left" rowspan="1" colspan="1">PD</td>
                        <td align="left" rowspan="1" colspan="1">2</td>
                        <td align="left" rowspan="1" colspan="1">57</td>
                        <td align="left" rowspan="1" colspan="1">1.9</td>
                        <td align="left" rowspan="1" colspan="1">1.9</td>
                        <td align="left" rowspan="1" colspan="1">3.2+</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">12</td>
                        <td align="left" rowspan="1" colspan="1">Anaplastic Astrocytoma</td>
                        <td align="left" rowspan="1" colspan="1">3</td>
                        <td align="left" rowspan="1" colspan="1">SD</td>
                        <td align="left" rowspan="1" colspan="1">10</td>
                        <td align="left" rowspan="1" colspan="1">279</td>
                        <td align="left" rowspan="1" colspan="1">9.3</td>
                        <td align="left" rowspan="1" colspan="1">9.2</td>
                        <td align="left" rowspan="1" colspan="1">10.9+</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">13</td>
                        <td align="left" rowspan="1" colspan="1">Oligodendroglioma</td>
                        <td align="left" rowspan="1" colspan="1">2</td>
                        <td align="left" rowspan="1" colspan="1">SD</td>
                        <td align="left" rowspan="1" colspan="1">4</td>
                        <td align="left" rowspan="1" colspan="1">110</td>
                        <td align="left" rowspan="1" colspan="1">3.7</td>
                        <td align="left" rowspan="1" colspan="1">3.6</td>
                        <td align="left" rowspan="1" colspan="1">19.9</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">14</td>
                        <td align="left" rowspan="1" colspan="1">Oligodendroglioma</td>
                        <td align="left" rowspan="1" colspan="1">2</td>
                        <td align="left" rowspan="1" colspan="1">SD</td>
                        <td align="left" rowspan="1" colspan="1">5</td>
                        <td align="left" rowspan="1" colspan="1">120</td>
                        <td align="left" rowspan="1" colspan="1">4.0</td>
                        <td align="left" rowspan="1" colspan="1">4</td>
                        <td align="left" rowspan="1" colspan="1">9.1+</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">15</td>
                        <td align="left" rowspan="1" colspan="1">Glioblastoma</td>
                        <td align="left" rowspan="1" colspan="1">4</td>
                        <td align="left" rowspan="1" colspan="1">PD</td>
                        <td align="left" rowspan="1" colspan="1">2</td>
                        <td align="left" rowspan="1" colspan="1">54</td>
                        <td align="left" rowspan="1" colspan="1">1.8</td>
                        <td align="left" rowspan="1" colspan="1">1.8</td>
                        <td align="left" rowspan="1" colspan="1">26.1+</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn>
                      <p>NOTE: PFS defined as the duration of time from start of treatment to time of progression or death, whichever occurs first. OS calculated from initiation of treatment to date of death or last known date of contact. + = alive or lost to follow-up.</p>
                    </fn>
                    <fn id="tb4fn1">
                      <p><sup>a</sup>Results of review of patient's MRIs by CTEP-appointed independent neuroradiologist demonstrated progressive disease at end of cycle 6 (day 166 of study). Patient was treated for four additional cycles after progression.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>In the whole study population, the median PFS was 3.63 months (95% CI, 1.87–5.53; <xref rid="fig2" ref-type="fig">Fig. 2A</xref>), median OS was 20.73 months (95% CI, 13.77–not reached [NR]; <xref rid="fig2" ref-type="fig">Fig. 2B</xref>), median number of cycles completed was 4 (range, 2–14), and the median number of months on treatment was 3.7 (range, 1.8–12.1). The study did not meet the prespecified response-based threshold for moving to stage 2.</p>
                <fig position="float" id="fig2">
                  <label>FIGURE 2</label>
                  <caption>
                    <p>Kaplan–Meier survival curves. <bold>A,</bold> PFS among all patients. <bold>B,</bold> OS among all patients. <bold>C,</bold> PFS comparing patients with grade 4 disease by histology or CDKN2A alteration to those with grade 2 or 3 disease (the log-rank test <italic toggle="yes">P</italic> value is reported). <bold>D,</bold> OS comparing patients with grade 4 disease by histology or CDKN2A alteration to those with grades 2 or 3 disease (log-rank test <italic toggle="yes">P</italic> value is reported).</p>
                  </caption>
                  <graphic xlink:href="crc-22-0436_fig2" position="float"/>
                </fig>
                <p>We compared PFS and OS of patients with WHO grade 2 or 3 lesions based on archived tissue from diagnosis, to those with grade 4 by histology or CDKN2A alteration. The median PFS of patients with grade 2 and/or 3 was 5.23 months (95% CI, 3.63–9.2) while those with grade 4 was 1.8 months (95% CI, 1.77–NR; log-rank test <italic toggle="yes">P</italic> = 0.0013 <xref rid="fig2" ref-type="fig">Fig. 2C</xref>). The median OS of patients with grade 2/3 disease was 29.5 months (95% CI, 19.87–NR) vs. 15.17 months (95% CI, 9.1–NR) for grade 4 tumors (<italic toggle="yes">P</italic> = 0.21; <xref rid="fig2" ref-type="fig">Fig. 2D</xref>).</p>
                <p>Reevaluation of imaging of all patients by a blinded NCI-designated neuroradiologist was performed. Two discordant results were identified: one patient's tumor had progressed after six cycles of treatment but was kept on for four additional cycles by the enrolling site. The corrected months of progression-free disease was reported in the above data. The second patient with discordant results had been taken off treatment due to PD after five cycles by their treating physician. However, reassessment of their scans demonstrated SD.</p>
              </sec>
            </sec>
            <sec sec-type="discussion" id="sec4">
              <title>Discussion</title>
              <p>Olaparib monotherapy was well tolerated in patients with recurrent or progressive contrast-enhancing <italic toggle="yes">IDH1/2</italic>mt glioma but did not meet prespecified response-based activity criteria for moving to stage 2 of the trial. However, clinically significant prolonged SD was observed in a relatively large proportion of patients, particularly those with WHO grades 2 and 3 histologies, suggesting olaparib monotherapy could be of clinical benefit in select patients. Grade 4 tumors, as defined by the 2021 WHO classification using histology or presence of <italic toggle="yes">CDKN2A</italic> deletion, derived minimal or no benefit from this drug demonstrating the utility of this new classification for possible future patient stratification and trial design.</p>
              <p>PARP is important in the repair of single-strand breaks (<xref rid="bib26" ref-type="bibr">26</xref>). In PARP inhibited cells, single-strand breaks accumulate and become more lethal double-strand breaks in the process of DNA replication. Cells with BRCA1 or BRCA2 mutations have defects in homologous recombination repair of double-strand DNA breaks. Patients with BRCA1- and BRCA2-mutated tumors treated with PARPis often have dramatic treatment responses as the synthetic lethality induced by the PARPi leads to cell death within the tumor (<xref rid="bib27" ref-type="bibr">27, 28</xref>). Favorable responses to PARPi have also been seen in tumors with DNA repair alterations other than BRCA mutations (<xref rid="bib29" ref-type="bibr">29, 30</xref>). Despite preclinical susceptibility of <italic toggle="yes">IDH1/2</italic>mt tumors to PARPi, our trial did not meet the prespecified endpoint of ORR to unequivocally demonstrate biological activity deriving from the “BRCAness” effects associated with 2-HG. However, the PFS data and disease stability observed in a relatively large proportion of patients (60%) raises the question of whether PARPi could still be of clinical benefit in these patients, in the absence of measurable tumor shrinkage. While our findings may suggest potential benefit in patients with lower grade histologies or at earlier stages of disease progression, further investigation is required as such phenotypes are inherently less aggressive. Other trials have studied PARPi in patients with gliomas, but their inclusion criteria likely excluded most patients with <italic toggle="yes">IDH1/2</italic>mt and/or other homologous recombination defects (<xref rid="bib31" ref-type="bibr">31, 32</xref>). In our trial, selection of patients based on contrast enhancement was an attempt to focus on the patients with <italic toggle="yes">IDH</italic>mt tumors of a higher grade or more aggressive behavior. However, the molecular heterogeneity of patients included in our study, patients’ enrollment at varying stages in their tumor's natural history, the small number of patients with oligodendroglioma, and differences in timing of collection of molecular information (at diagnosis vs. at time of recurrence) limit the conclusions that can be drawn from our data. Regardless, it is clear from the results of this trial that single-agent olaparib is not a sufficient treatment for grade 4 gliomas.</p>
              <p>Recently, preliminary results of the OLAGLI trial investigating olaparib in 35 patients with recurrent <italic toggle="yes">IDH1/2</italic>mt high-grade contrast-enhancing gliomas were presented at American Society of Clinical Oncology 2021 (<xref rid="bib33" ref-type="bibr">33</xref>). That study found a 6-month PFS rate of 31%, which did not meet prespecified threshold for significance, but 2 patients (5%) had a PR and 14 patients (40%) achieved SD. The median duration of response in the combined PR and SD patients was 9 months. The median OS was 15.9 months (<xref rid="bib33" ref-type="bibr">33</xref>). Similar to our study, these preliminary results suggest that there may be patients who experience clinically meaningful benefit from single-agent PARPi through disease stability, although olaparib's activity as a single agent as measured by radiographic responses and tumor shrinkage is modest.</p>
              <p>An important concern in the development of novel therapies for CNS tumors is the ability of novel agents to penetrate through areas of intact blood–brain barrier to address infiltrative disease. CNS penetration of olaparib in humans has been shown in a phase I study combining temozolomide with olaparib in patients with relapsed glioblastoma; olaparib, given prior to surgery, was detected in 71 of 71 tumor core specimens from 27 patients (<xref rid="bib34" ref-type="bibr">34</xref>). Detected drug levels were greater than 100 nmol/L, the concentration determined by <italic toggle="yes">in vitro</italic> experiments to be needed for maximal PARP inhibition (<xref rid="bib35" ref-type="bibr">35</xref>). Trials are ongoing investigating novel PARPis with potential for even greater brain penetration (NCT00687765, NCT03914742).</p>
              <p>Identifying mutations that further define distinct subgroups within <italic toggle="yes">IDH</italic>mt glioma for updated grading and selection of patients who may benefit from PARPi remains of high interest. Homozygous deletion of <italic toggle="yes">CDKN2A</italic> has been noted to be an adverse prognostic factor associated with worse PFS and OS in patients with <italic toggle="yes">IDH1/2</italic>mt disease (<xref rid="bib36" ref-type="bibr">36, 37</xref>) and per the 2021 WHO classification of tumors confers grade 4 status (<xref rid="bib6" ref-type="bibr">6</xref>). In our study, 4 of 5 patients with known <italic toggle="yes">CDKN2A</italic> alteration progressed on first restaging. Our findings therefore seem to support the inclusion of <italic toggle="yes">CDKN2A</italic> status as a grade-defining molecular finding for the grading of gliomas, as acknowledged in this new classification of gliomas by the WHO. A limitation in our observation is that <italic toggle="yes">CDKN2A</italic> copy-number status was assessed by next-generation sequencing (NGS) performed locally, and the distinction between homozygous and heterozygous deletion was not uniformly provided. While in <italic toggle="yes">IDH</italic> wildtype glioblastoma <italic toggle="yes">CDKN2A</italic> deletions are nearly universally homozygous, we acknowledge that in some patients with <italic toggle="yes">IDH1/2</italic>mt gliomas, the <italic toggle="yes">CDKN2A</italic> deletion as determined by NGS may not be homozygous. Therefore, it is possible, but unlikely, that the 2 patients with poor outcomes that were reclassified as grade 4 per WHO 2021 may not meet criteria for such, should other methods for <italic toggle="yes">CDKN2A</italic> evaluation be utilized.</p>
              <p>In addition to PARPi, a significant focus of research in <italic toggle="yes">IDH1/2</italic>mt gliomas is on direct inhibition of <italic toggle="yes">IDH</italic>mt proteins. In a phase I trial, 30 patients with recurrent or progressive <italic toggle="yes">IDH1/2</italic>mt enhancing glioma received vorasidenib, an oral, brain-penetrant inhibitor of <italic toggle="yes">IDH1/2</italic>mt. ORR was 0% but 56.7% of patients achieved SD. The median PFS was 3.6 months, similar to our trial (<xref rid="bib19" ref-type="bibr">19</xref>). A window-of-opportunity trial of vorasidenib and the <italic toggle="yes">IDH1</italic> inhibitor ivosidenib randomized patients with recurrent nonenhancing WHO 2016 grade 2 or 3 <italic toggle="yes">IDH1</italic>mt glioma who were undergoing craniotomy to receive either ivosidenib, vorasidenib, or no treatment for 4 weeks preoperatively. Postoperatively, they were randomized to ivosidenib or vorasidenib. Both drugs were found to be CNS penetrant (brain:plasma ratio 0.16 for ivosidenib and 2.4 for vorasidenib) and both lowered 2HG levels compared with untreated samples (<xref rid="bib21" ref-type="bibr">21</xref>). ORR was 30.8%. Switching to a focus on earlier stage disease, the phase III INDIGO trial is randomizing <italic toggle="yes">IDH1/2</italic>mt residual or recurrent grade 2, nonenhancing glioma to receive vorasidenib or placebo, with primary endpoint of PFS (<xref rid="bib38" ref-type="bibr">38</xref>).</p>
              <p>There are numerous future study directions in this population. Trials investigating timing of <italic toggle="yes">IDH</italic>-targeted therapy with <italic toggle="yes">IDH</italic> inhibitors or PARPi in the first-line (NCT03581292) or recurrent/relapsed setting and timing with respect to surgery will be important. An ongoing study is investigating the effect of niraparib prior to surgery in <italic toggle="yes">IDH</italic>mt glioma (NCT05076513). Studies that compare responses in patients with contrast-enhancing and non–contrast-enhancing tumors will also provide information on which populations are most likely to benefit. Outcomes of treatment with PARPi in patients who have received prior treatment with IDH inhibitors are currently being investigated in a phase II clinical trial (NCT03212274). Finally, it is possible that PARPi may require combination with additional therapies to improve activity and induce tumor shrinkage. A single-center retrospective study reported the results of patients with glioma, some with <italic toggle="yes">IDH1/</italic>2mt, who were treated with combination olaparib and temozolomide. Four of the 8 patients with grade 2 or 3 <italic toggle="yes">IDH</italic>mt disease had complete or partial response. Consistent with our findings, no responses were seen in patients with grade 4 <italic toggle="yes">IDH</italic>mt glioma. This trial suggests promise of olaparib in combination but is limited by its retrospective design (<xref rid="bib39" ref-type="bibr">39</xref>). Other ongoing trials investigating combination therapy include PARPi + PD-L1 inhibitor (NCT03991832), PARPi + temozolomide (NCT02152982, NCT04552977, NCT01390571, NCT04910022, NCT03581292, NCT03749187, NCT03914742, NCT03212742), and PARPi + temozolomide + radiotherapy (NCT04614909). Taken together, this body of work will establish whether PARPi will eventually play a meaningful role in the treatment of gliomas.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supplementary Material</title>
              <supplementary-material id="SMD1" position="float" content-type="local-data">
                <label>Supplementary Data</label>
                <caption>
                  <p>Definition of Progression, Tumor Classification, and Eligibility Criteria, retreatment criteria</p>
                </caption>
                <media xlink:href="crc-22-0436-s01.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="SMT1" position="float" content-type="local-data">
                <label>Supplementary Table 1</label>
                <caption>
                  <p>Representativeness of Study Participants</p>
                </caption>
                <media xlink:href="crc-22-0436-s02.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack>
              <title>Acknowledgments</title>
              <p>The authors would like to thank CTEP, The Catherine Ivy Foundation, and The Rising Tide Foundation for their support of this project through grants to P. LoRusso.</p>
            </ack>
            <fn-group>
              <fn fn-type="supplementary-material">
                <p><bold>Note:</bold> Supplementary data for this article are available at Cancer Research Communications Online (<ext-link xlink:href="https://aacrjournals.org/cancerrescommun/" ext-link-type="uri" xlink:show="new">https://aacrjournals.org/cancerrescommun/</ext-link>).</p>
              </fn>
            </fn-group>
            <sec sec-type="COI-statement" id="sec5">
              <title>Authors’ Disclosures</title>
              <p>Y. Shyr reports grants from NIH/NCI during the conduct of the study; grants from NIH outside the submitted work. S. Boerner reports grants from NCI-CTEP and Rising Tide Foundation during the conduct of the study. D. Durecki reports grants from NIH/NCI UM1CA186689 during the conduct of the study. J. Drappatz reports other from Pfizer, GSK, Gilead, and Vertex outside the submitted work. V. Puduvalli reports personal fees and other from Servier and Novocure, other from Karyopharm, and personal fees from Orbus therapeutics during the conduct of the study; other from Amarin and Gilead outside the submitted work. F.S. Lieberman reports grants from ABTC during the conduct of the study; grants from Novocure, Chimerix, Blue Diamond Therapeutics, and Abbvie outside the submitted work. J. Gonzalez reports other from AstraZeneca outside the submitted work. P. Giglio reports grants from NCI during the conduct of the study; other from Vanguard Funds; grants from BioMimetix, Denovo Biopharma, Institut de Recherches Internationales Servier, Novocure, and Prelude Therapeutics outside the submitted work. R.S. Bindra reports a patent to 62/344,678 pending. A. Omuro reports grants from Arcus Biosciences; personal fees from Pyramid, Merck, Kiyatec, and Ono outside the submitted work. P. LoRusso reports other from AbbVie, Agios, Five Prime, GenMab, Halozyme, Roche-Genetech, Genentech, CytomX, Takeda, Sotio, Cybrexa, Agenus, Tyme, IQVIA, TRIGR, Pfizer, ImmunoMet, Black Diamond, Glaxo-Smith Kline, QED Therapeutics, AstraZeneca, EMD Serono, Shattuck, Astellas, Salarius, Silverback, MacroGenics, Kyowa Kirin Pharmaceutical, Kineta, Zentalis, Molecular Templates, ABL Bio, SK Life Science, STCube Pharmaceuticals, Bayer, I-Mab, Seagen, imCheck, Relay Therapeutics, Stemline, Compass BADX, Mekanist, Mersana Therapeutics, BAKX Therapeutics, Scenic Biotech, Qualigen, Roivant, and NeuroTrials outside the submitted work. No disclosures were reported by the other authors.</p>
            </sec>
            <sec id="sec6">
              <title>Authors’ Contributions</title>
              <p><bold>K. Fanucci:</bold> Data curation, formal analysis, visualization, writing-original draft, writing-review and editing. <bold>M.J. Pilat:</bold> Conceptualization, data curation, formal analysis, writing-original draft, writing-review and editing. <bold>D. Shyr:</bold> Formal analysis, visualization, writing-review and editing. <bold>Y. Shyr:</bold> Conceptualization, formal analysis, visualization, methodology, writing-review and editing. <bold>S. Boerner:</bold> Conceptualization, resources, investigation, project administration, writing-review and editing. <bold>J. Li:</bold> Formal analysis, writing-review and editing. <bold>D. Durecki:</bold> Resources, data curation, project administration, writing-review and editing. <bold>J. Drappatz:</bold> Conceptualization, data curation, writing-review and editing. <bold>V. Puduvalli:</bold> Resources, data curation, writing-review and editing. <bold>F.S. Lieberman:</bold> Resources, data curation, writing-review and editing. <bold>J. Gonzalez:</bold> Resources, data curation, writing-review and editing. <bold>P. Giglio:</bold> Resources, data curation, writing-review and editing. <bold>S.P. Ivy:</bold> Conceptualization, project administration, writing-review and editing. <bold>R.S. Bindra:</bold> Conceptualization, funding acquisition, writing-original draft, writing-review and editing. <bold>A. Omuro:</bold> Formal analysis, supervision, validation, writing-original draft, writing-review and editing. <bold>P. LoRusso:</bold> Conceptualization, resources, data curation, supervision, funding acquisition, validation, investigation, methodology, writing-original draft, writing-review and editing.</p>
            </sec>
            <ref-list>
              <title>References</title>
              <ref id="bib1">
                <label>1.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ostrom</surname><given-names>QT</given-names></string-name>, <string-name><surname>Gittleman</surname><given-names>H</given-names></string-name>, <string-name><surname>Xu</surname><given-names>J</given-names></string-name>, <string-name><surname>Kromer</surname><given-names>C</given-names></string-name>, <string-name><surname>Wolinsky</surname><given-names>Y</given-names></string-name>, <string-name><surname>Kruchko</surname><given-names>C</given-names></string-name>, <etal/></person-group>. <article-title>CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2009–2013</article-title>. <source>Neuro Oncol</source><year>2016</year>;<volume>18</volume>:<fpage>v1</fpage>–<lpage>75</lpage>.<pub-id pub-id-type="pmid">28475809</pub-id></mixed-citation>
              </ref>
              <ref id="bib2">
                <label>2.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yan</surname><given-names>H</given-names></string-name>, <string-name><surname>Parsons</surname><given-names>DW</given-names></string-name>, <string-name><surname>Jin</surname><given-names>G</given-names></string-name>, <string-name><surname>McLendon</surname><given-names>R</given-names></string-name>, <string-name><surname>Rasheed</surname><given-names>BA</given-names></string-name>, <string-name><surname>Yuan</surname><given-names>W</given-names></string-name>, <etal/></person-group>. <article-title>IDH1 and IDH2 mutations in gliomas</article-title>. <source>N Engl J Med</source><year>2009</year>;<volume>360</volume>:<fpage>765</fpage>–<lpage>73</lpage>.<pub-id pub-id-type="pmid">19228619</pub-id></mixed-citation>
              </ref>
              <ref id="bib3">
                <label>3.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Reuss</surname><given-names>DE</given-names></string-name>, <string-name><surname>Mamatjan</surname><given-names>Y</given-names></string-name>, <string-name><surname>Schrimpf</surname><given-names>D</given-names></string-name>, <string-name><surname>Capper</surname><given-names>D</given-names></string-name>, <string-name><surname>Hovestadt</surname><given-names>V</given-names></string-name>, <string-name><surname>Kratz</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO</article-title>. <source>Acta Neuropathol</source><year>2015</year>;<volume>129</volume>:<fpage>867</fpage>–<lpage>73</lpage>.<pub-id pub-id-type="pmid">25962792</pub-id></mixed-citation>
              </ref>
              <ref id="bib4">
                <label>4.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Louis</surname><given-names>DN</given-names></string-name>, <string-name><surname>Perry</surname><given-names>A</given-names></string-name>, <string-name><surname>Reifenberger</surname><given-names>G</given-names></string-name>, <string-name><surname>von Deimling</surname><given-names>A</given-names></string-name>, <string-name><surname>Figarella-Branger</surname><given-names>D</given-names></string-name>, <string-name><surname>Cavenee</surname><given-names>WK</given-names></string-name>, <etal/></person-group>. <article-title>The 2016 World Health Organization classification of tumors of the central nervous system: a summary</article-title>. <source>Acta Neuropathol</source><year>2016</year>;<volume>131</volume>:<fpage>803</fpage>–<lpage>20</lpage>.<pub-id pub-id-type="pmid">27157931</pub-id></mixed-citation>
              </ref>
              <ref id="bib5">
                <label>5.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bai</surname><given-names>H</given-names></string-name>, <string-name><surname>Harmancı</surname><given-names>AS</given-names></string-name>, <string-name><surname>Erson-Omay</surname><given-names>EZ</given-names></string-name>, <string-name><surname>Li</surname><given-names>J</given-names></string-name>, <string-name><surname>Coşkun</surname><given-names>S</given-names></string-name>, <string-name><surname>Simon</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>Integrated genomic characterization of IDH1-mutant glioma malignant progression</article-title>. <source>Nat Genet</source><year>2016</year>;<volume>48</volume>:<fpage>59</fpage>–<lpage>66</lpage>.<pub-id pub-id-type="pmid">26618343</pub-id></mixed-citation>
              </ref>
              <ref id="bib6">
                <label>6.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Louis</surname><given-names>DN</given-names></string-name>, <string-name><surname>Perry</surname><given-names>A</given-names></string-name>, <string-name><surname>Wesseling</surname><given-names>P</given-names></string-name>, <string-name><surname>Brat</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Cree</surname><given-names>IA</given-names></string-name>, <string-name><surname>Figarella-Branger</surname><given-names>D</given-names></string-name>, <etal/></person-group>. <article-title>The 2021 WHO classification of tumors of the central nervous system: a summary</article-title>. <source>Neuro-oncol</source><year>2021</year>;<volume>23</volume>:<fpage>1231</fpage>–<lpage>51</lpage>.<pub-id pub-id-type="pmid">34185076</pub-id></mixed-citation>
              </ref>
              <ref id="bib7">
                <label>7.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bell</surname><given-names>EH</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>P</given-names></string-name>, <string-name><surname>Shaw</surname><given-names>EG</given-names></string-name>, <string-name><surname>Buckner</surname><given-names>JC</given-names></string-name>, <string-name><surname>Barger</surname><given-names>GR</given-names></string-name>, <string-name><surname>Bullard</surname><given-names>DE</given-names></string-name>, <etal/></person-group>. <article-title>Comprehensive genomic analysis in NRG oncology/RTOG 9802: a phase III trial of radiation versus radiation plus procarbazine, lomustine (CCNU), and vincristine in high-risk low-grade glioma</article-title>. <source>J Clin Oncol</source><year>2020</year>;<volume>38</volume>:<fpage>3407</fpage>–<lpage>17</lpage>.<pub-id pub-id-type="pmid">32706640</pub-id></mixed-citation>
              </ref>
              <ref id="bib8">
                <label>8.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>van den Bent</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Brandes</surname><given-names>AA</given-names></string-name>, <string-name><surname>Taphoorn</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Kros</surname><given-names>JM</given-names></string-name>, <string-name><surname>Kouwenhoven</surname><given-names>MC</given-names></string-name>, <string-name><surname>Delattre</surname><given-names>JY</given-names></string-name>, <etal/></person-group>. <article-title>Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951</article-title>. <source>J Clin Oncol</source><year>2013</year>;<volume>31</volume>:<fpage>344</fpage>–<lpage>50</lpage>.<pub-id pub-id-type="pmid">23071237</pub-id></mixed-citation>
              </ref>
              <ref id="bib9">
                <label>9.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>van den Bent</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Tesileanu</surname><given-names>CMS</given-names></string-name>, <string-name><surname>Wick</surname><given-names>W</given-names></string-name>, <string-name><surname>Sanson</surname><given-names>M</given-names></string-name>, <string-name><surname>Brandes</surname><given-names>AA</given-names></string-name>, <string-name><surname>Clement</surname><given-names>PM</given-names></string-name>, <etal/></person-group>. <article-title>Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053–22054): second interim analysis of a randomised, open-label, phase 3 study</article-title>. <source>Lancet Oncol</source><year>2021</year>;<volume>22</volume>:<fpage>813</fpage>–<lpage>23</lpage>.<pub-id pub-id-type="pmid">34000245</pub-id></mixed-citation>
              </ref>
              <ref id="bib10">
                <label>10.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fisher</surname><given-names>BJ</given-names></string-name>, <string-name><surname>Hu</surname><given-names>C</given-names></string-name>, <string-name><surname>Macdonald</surname><given-names>DR</given-names></string-name>, <string-name><surname>Lesser</surname><given-names>GJ</given-names></string-name>, <string-name><surname>Coons</surname><given-names>SW</given-names></string-name>, <string-name><surname>Brachman</surname><given-names>DG</given-names></string-name>, <etal/></person-group>. <article-title>Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of radiation therapy oncology group 0424</article-title>. <source>Int J Radiat Oncol Biol Phys</source><year>2015</year>;<volume>91</volume>:<fpage>497</fpage>–<lpage>504</lpage>.<pub-id pub-id-type="pmid">25680596</pub-id></mixed-citation>
              </ref>
              <ref id="bib11">
                <label>11.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gilbert</surname><given-names>MR</given-names></string-name>, <string-name><surname>Wang</surname><given-names>M</given-names></string-name>, <string-name><surname>Aldape</surname><given-names>KD</given-names></string-name>, <string-name><surname>Stupp</surname><given-names>R</given-names></string-name>, <string-name><surname>Hegi</surname><given-names>ME</given-names></string-name>, <string-name><surname>Jaeckle</surname><given-names>KA</given-names></string-name>, <etal/></person-group>. <article-title>Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial</article-title>. <source>J Clin Oncol</source><year>2013</year>;<volume>31</volume>:<fpage>4085</fpage>–<lpage>91</lpage>.<pub-id pub-id-type="pmid">24101040</pub-id></mixed-citation>
              </ref>
              <ref id="bib12">
                <label>12.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Han</surname><given-names>S</given-names></string-name>, <string-name><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name><surname>Cai</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Qian</surname><given-names>M</given-names></string-name>, <string-name><surname>Ding</surname><given-names>J</given-names></string-name>, <string-name><surname>Larion</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>IDH mutation in glioma: molecular mechanisms and potential therapeutic targets</article-title>. <source>Br J Cancer</source><year>2020</year>;<volume>122</volume>:<fpage>1580</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">32291392</pub-id></mixed-citation>
              </ref>
              <ref id="bib13">
                <label>13.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dang</surname><given-names>L</given-names></string-name>, <string-name><surname>White</surname><given-names>DW</given-names></string-name>, <string-name><surname>Gross</surname><given-names>S</given-names></string-name>, <string-name><surname>Bennett</surname><given-names>BD</given-names></string-name>, <string-name><surname>Bittinger</surname><given-names>MA</given-names></string-name>, <string-name><surname>Driggers</surname><given-names>EM</given-names></string-name>, <etal/></person-group>. <article-title>Cancer-associated IDH1 mutations produce 2-hydroxyglutarate</article-title>. <source>Nature</source><year>2010</year>;<volume>465</volume>:<fpage>966</fpage>.<pub-id pub-id-type="pmid">20559394</pub-id></mixed-citation>
              </ref>
              <ref id="bib14">
                <label>14.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xu</surname><given-names>W</given-names></string-name>, <string-name><surname>Yang</surname><given-names>H</given-names></string-name>, <string-name><surname>Liu</surname><given-names>Y</given-names></string-name>, <string-name><surname>Yang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Wang</surname><given-names>P</given-names></string-name>, <string-name><surname>Kim</surname><given-names>SH</given-names></string-name>, <etal/></person-group>. <article-title>Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases</article-title>. <source>Cancer Cell</source><year>2011</year>;<volume>19</volume>:<fpage>17</fpage>–<lpage>30</lpage>.<pub-id pub-id-type="pmid">21251613</pub-id></mixed-citation>
              </ref>
              <ref id="bib15">
                <label>15.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Stein</surname><given-names>EM</given-names></string-name>, <string-name><surname>Fathi</surname><given-names>AT</given-names></string-name>, <string-name><surname>DiNardo</surname><given-names>CD</given-names></string-name>, <string-name><surname>Pollyea</surname><given-names>DA</given-names></string-name>, <string-name><surname>Roboz</surname><given-names>GJ</given-names></string-name>, <string-name><surname>Collins</surname><given-names>R</given-names></string-name>, <etal/></person-group>. <article-title>Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial</article-title>. <source>Lancet Haematol</source><year>2020</year>;<volume>7</volume>:<fpage>e309</fpage>–<lpage>19</lpage>.<pub-id pub-id-type="pmid">32145771</pub-id></mixed-citation>
              </ref>
              <ref id="bib16">
                <label>16.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>DiNardo</surname><given-names>CD</given-names></string-name>, <string-name><surname>Stein</surname><given-names>EM</given-names></string-name>, <string-name><surname>de Botton</surname><given-names>S</given-names></string-name>, <string-name><surname>Roboz</surname><given-names>GJ</given-names></string-name>, <string-name><surname>Altman</surname><given-names>JK</given-names></string-name>, <string-name><surname>Mims</surname><given-names>AS</given-names></string-name>, <etal/></person-group>. <article-title>Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML</article-title>. <source>N Engl J Med</source><year>2018</year>;<volume>378</volume>:<fpage>2386</fpage>–<lpage>98</lpage>.<pub-id pub-id-type="pmid">29860938</pub-id></mixed-citation>
              </ref>
              <ref id="bib17">
                <label>17.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Abou-Alfa</surname><given-names>GK</given-names></string-name>, <string-name><surname>Macarulla</surname><given-names>T</given-names></string-name>, <string-name><surname>Javle</surname><given-names>MM</given-names></string-name>, <string-name><surname>Kelley</surname><given-names>RK</given-names></string-name>, <string-name><surname>Lubner</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Adeva</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study</article-title>. <source>Lancet Oncol</source><year>2020</year>;<volume>21</volume>:<fpage>796</fpage>–<lpage>807</lpage>.<pub-id pub-id-type="pmid">32416072</pub-id></mixed-citation>
              </ref>
              <ref id="bib18">
                <label>18.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mellinghoff</surname><given-names>IK</given-names></string-name>, <string-name><surname>Ellingson</surname><given-names>BM</given-names></string-name>, <string-name><surname>Touat</surname><given-names>M</given-names></string-name>, <string-name><surname>Maher</surname><given-names>E</given-names></string-name>, <string-name><surname>De La Fuente</surname><given-names>MI</given-names></string-name>, <string-name><surname>Holdhoff</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>Ivosidenib in isocitrate dehydrogenase 1-mutated advanced glioma</article-title>. <source>J Clin Oncol</source><year>2020</year>;<volume>38</volume>:<fpage>3398</fpage>–<lpage>406</lpage>.<pub-id pub-id-type="pmid">32530764</pub-id></mixed-citation>
              </ref>
              <ref id="bib19">
                <label>19.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mellinghoff</surname><given-names>IK</given-names></string-name>, <string-name><surname>Penas-Prado</surname><given-names>M</given-names></string-name>, <string-name><surname>Peters</surname><given-names>KB</given-names></string-name>, <string-name><surname>Burris</surname><given-names>HA</given-names><suffix>3rd</suffix></string-name>, <string-name><surname>Maher</surname><given-names>EA</given-names></string-name>, <string-name><surname>Janku</surname><given-names>F</given-names></string-name>, <etal/></person-group>. <article-title>Vorasidenib, a dual inhibitor of mutant IDH1/2, in recurrent or progressive glioma; results of a first-in-human phase I trial</article-title>. <source>Clin Cancer Res</source><year>2021</year>;<volume>27</volume>:<fpage>4491</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">34078652</pub-id></mixed-citation>
              </ref>
              <ref id="bib20">
                <label>20.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mellinghoff</surname><given-names>IK</given-names></string-name>, <string-name><surname>Peters</surname><given-names>KB</given-names></string-name>, <string-name><surname>Cloughesy</surname><given-names>TF</given-names></string-name>, <string-name><surname>Burris Iii</surname><given-names>HA</given-names></string-name>, <string-name><surname>Maher</surname><given-names>EA</given-names></string-name>, <string-name><surname>Janku</surname><given-names>F</given-names></string-name>, <etal/></person-group>. <article-title>Vorasidenib (VOR; AG-881), an inhibitor of mutant IDH1 and IDH2, in patients (pts) with recurrent/progressive glioma: updated results from the phase I non-enhancing glioma population</article-title>. <source>J Clin Oncol</source><year>2020</year>;<volume>38</volume>:<fpage>15s</fpage>, (suppl; abstr 2504).</mixed-citation>
              </ref>
              <ref id="bib21">
                <label>21.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mellinghoff</surname><given-names>IK</given-names></string-name>, <string-name><surname>Wen</surname><given-names>PY</given-names></string-name>, <string-name><surname>Taylor</surname><given-names>JW</given-names></string-name>, <string-name><surname>Maher</surname><given-names>EA</given-names></string-name>, <string-name><surname>Arrillaga-Romany</surname><given-names>I</given-names></string-name>, <string-name><surname>Peters</surname><given-names>KB</given-names></string-name>, <etal/></person-group>. <article-title>PL3.1 A phase 1, open-label, perioperative study of ivosidenib (AG-120) and vorasidenib (AG-881) in recurrent, IDH1-mutant, low-grade glioma: results from cohort 1</article-title>. <source>Neuro Oncol</source><year>2019</year>;<volume>21</volume>:<fpage>iii2</fpage>.</mixed-citation>
              </ref>
              <ref id="bib22">
                <label>22.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sulkowski</surname><given-names>PL</given-names></string-name>, <string-name><surname>Corso</surname><given-names>CD</given-names></string-name>, <string-name><surname>Robinson</surname><given-names>ND</given-names></string-name>, <string-name><surname>Scanlon</surname><given-names>SE</given-names></string-name>, <string-name><surname>Purshouse</surname><given-names>KR</given-names></string-name>, <string-name><surname>Bai</surname><given-names>H</given-names></string-name>, <etal/></person-group>. <article-title>2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity</article-title>. <source>Sci Transl Med</source><year>2017</year>;<volume>9</volume>:<fpage>eaal2463</fpage>.<pub-id pub-id-type="pmid">28148839</pub-id></mixed-citation>
              </ref>
              <ref id="bib23">
                <label>23.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Salinas</surname><given-names>B</given-names></string-name>, <string-name><surname>Irwin</surname><given-names>CP</given-names></string-name>, <string-name><surname>Kossatz</surname><given-names>S</given-names></string-name>, <string-name><surname>Bolaender</surname><given-names>A</given-names></string-name>, <string-name><surname>Chiosis</surname><given-names>G</given-names></string-name>, <string-name><surname>Pillarsetty</surname><given-names>N</given-names></string-name>, <etal/></person-group>. <article-title>Radioiodinated PARP1 tracers for glioblastoma imaging</article-title>. <source>EJNMMI Res</source><year>2015</year>;<volume>5</volume>:<fpage>123</fpage>.<pub-id pub-id-type="pmid">26337803</pub-id></mixed-citation>
              </ref>
              <ref id="bib24">
                <label>24.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lesueur</surname><given-names>P</given-names></string-name>, <string-name><surname>Lequesne</surname><given-names>J</given-names></string-name>, <string-name><surname>Grellard</surname><given-names>JM</given-names></string-name>, <string-name><surname>Dugué</surname><given-names>A</given-names></string-name>, <string-name><surname>Coquan</surname><given-names>E</given-names></string-name>, <string-name><surname>Brachet</surname><given-names>PE</given-names></string-name>, <etal/></person-group>. <article-title>Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol</article-title>. <source>BMC Cancer</source><year>2019</year>;<volume>19</volume>:<fpage>198</fpage>.<pub-id pub-id-type="pmid">30832617</pub-id></mixed-citation>
              </ref>
              <ref id="bib25">
                <label>25.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bochum</surname><given-names>S</given-names></string-name>, <string-name><surname>Berger</surname><given-names>S</given-names></string-name>, <string-name><surname>Martens</surname><given-names>UM</given-names></string-name></person-group>. <source>Recent Results Cancer Res</source><year>2018</year>;<volume>211</volume>:<fpage>217</fpage>–<lpage>33</lpage>.<pub-id pub-id-type="pmid">30069770</pub-id></mixed-citation>
              </ref>
              <ref id="bib26">
                <label>26.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Murai</surname><given-names>J</given-names></string-name>, <string-name><surname>Huang</surname><given-names>SY</given-names></string-name>, <string-name><surname>Renaud</surname><given-names>A</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Ji</surname><given-names>J</given-names></string-name>, <string-name><surname>Takeda</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib</article-title>. <source>Mol Cancer Ther</source><year>2014</year>;<volume>13</volume>:<fpage>433</fpage>–<lpage>43</lpage>.<pub-id pub-id-type="pmid">24356813</pub-id></mixed-citation>
              </ref>
              <ref id="bib27">
                <label>27.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhao</surname><given-names>W</given-names></string-name>, <string-name><surname>Wiese</surname><given-names>C</given-names></string-name>, <string-name><surname>Kwon</surname><given-names>Y</given-names></string-name>, <string-name><surname>Hromas</surname><given-names>R</given-names></string-name>, <string-name><surname>Sung</surname><given-names>P</given-names></string-name></person-group>. <article-title>The BRCA tumor suppressor network in chromosome damage repair by homologous recombination</article-title>. <source>Annu Rev Biochem</source><year>2019</year>;<volume>88</volume>:<fpage>221</fpage>–<lpage>45</lpage>.<pub-id pub-id-type="pmid">30917004</pub-id></mixed-citation>
              </ref>
              <ref id="bib28">
                <label>28.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lord</surname><given-names>CJ</given-names></string-name>, <string-name><surname>Ashworth</surname><given-names>A</given-names></string-name></person-group>. <article-title>PARP inhibitors: synthetic lethality in the clinic</article-title>. <source>Science</source><year>2017</year>;<volume>355</volume>:<fpage>1152</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">28302823</pub-id></mixed-citation>
              </ref>
              <ref id="bib29">
                <label>29.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bryant</surname><given-names>HE</given-names></string-name>, <string-name><surname>Schultz</surname><given-names>N</given-names></string-name>, <string-name><surname>Thomas</surname><given-names>HD</given-names></string-name>, <string-name><surname>Parker</surname><given-names>KM</given-names></string-name>, <string-name><surname>Flower</surname><given-names>D</given-names></string-name>, <string-name><surname>Lopez</surname><given-names>E</given-names></string-name>, <etal/></person-group>. <article-title>Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase</article-title>. <source>Nature</source><year>2005</year>;<volume>434</volume>:<fpage>913</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">15829966</pub-id></mixed-citation>
              </ref>
              <ref id="bib30">
                <label>30.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Farmer</surname><given-names>H</given-names></string-name>, <string-name><surname>McCabe</surname><given-names>N</given-names></string-name>, <string-name><surname>Lord</surname><given-names>CJ</given-names></string-name>, <string-name><surname>Tutt</surname><given-names>AN</given-names></string-name>, <string-name><surname>Johnson</surname><given-names>DA</given-names></string-name>, <string-name><surname>Richardson</surname><given-names>TB</given-names></string-name>, <etal/></person-group>. <article-title>Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy</article-title>. <source>Nature</source><year>2005</year>;<volume>434</volume>:<fpage>917</fpage>–<lpage>21</lpage>.<pub-id pub-id-type="pmid">15829967</pub-id></mixed-citation>
              </ref>
              <ref id="bib31">
                <label>31.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chalmers</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Jackson</surname><given-names>A</given-names></string-name>, <string-name><surname>Swaisland</surname><given-names>H</given-names></string-name>, <string-name><surname>Stewart</surname><given-names>W</given-names></string-name>, <string-name><surname>Halford</surname><given-names>SE</given-names></string-name>, <string-name><surname>Molife</surname><given-names>LR</given-names></string-name>, <etal/></person-group>. <article-title>Results of stage 1 of the oparatic trial: a phase I study of olaparib in combination with temozolomide in patients with relapsed glioblastoma</article-title>. <source>J Clin Oncol</source><year>2014</year>;<volume>32</volume>:<fpage>15s</fpage>,(suppl; abstr 2025).</mixed-citation>
              </ref>
              <ref id="bib32">
                <label>32.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Myung</surname><given-names>JK</given-names></string-name>, <string-name><surname>Cho</surname><given-names>HJ</given-names></string-name>, <string-name><surname>Kim</surname><given-names>H</given-names></string-name>, <string-name><surname>Park</surname><given-names>CK</given-names></string-name>, <string-name><surname>Lee</surname><given-names>SH</given-names></string-name>, <string-name><surname>Choi</surname><given-names>SH</given-names></string-name>, <etal/></person-group>. <article-title>Prognosis of glioblastoma with oligodendroglioma component is associated with the IDH1 mutation and MGMT methylation status</article-title>. <source>Transl Oncol</source><year>2014</year>;<volume>7</volume>:<fpage>712</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">25500080</pub-id></mixed-citation>
              </ref>
              <ref id="bib33">
                <label>33.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ducray</surname><given-names>F</given-names></string-name>, <string-name><surname>Sanson</surname><given-names>M</given-names></string-name>, <string-name><surname>Chinot</surname><given-names>OL</given-names></string-name>, <string-name><surname>Fontanilles</surname><given-names>M</given-names></string-name>, <string-name><surname>Rivoirard</surname><given-names>R</given-names></string-name>, <string-name><surname>Thomas-Maisonneuve</surname><given-names>L</given-names></string-name>, <etal/></person-group>. <article-title>Olaparib in recurrent IDH-mutant high-grade glioma (OLAGLI)</article-title>. <source>J Clin Oncol</source><year>2021</year>;<volume>39</volume>:<fpage>15s</fpage>, (suppl; abstr 2007).</mixed-citation>
              </ref>
              <ref id="bib34">
                <label>34.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hanna</surname><given-names>C</given-names></string-name>, <string-name><surname>Kurian</surname><given-names>KM</given-names></string-name>, <string-name><surname>Williams</surname><given-names>K</given-names></string-name>, <string-name><surname>Watts</surname><given-names>C</given-names></string-name>, <string-name><surname>Jackson</surname><given-names>A</given-names></string-name>, <string-name><surname>Carruthers</surname><given-names>R</given-names></string-name>, <etal/></person-group>. <article-title>Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial</article-title>. <source>Neuro Oncol</source><year>2020</year>;<volume>22</volume>:<fpage>1840</fpage>–<lpage>50</lpage>.<pub-id pub-id-type="pmid">32347934</pub-id></mixed-citation>
              </ref>
              <ref id="bib35">
                <label>35.</label>
                <mixed-citation publication-type="other">206162 Clinical Pharmacology Review; <year>2014</year>.</mixed-citation>
              </ref>
              <ref id="bib36">
                <label>36.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Appay</surname><given-names>R</given-names></string-name>, <string-name><surname>Dehais</surname><given-names>C</given-names></string-name>, <string-name><surname>Maurage</surname><given-names>CA</given-names></string-name>, <string-name><surname>Alentorn</surname><given-names>A</given-names></string-name>, <string-name><surname>Carpentier</surname><given-names>C</given-names></string-name>, <string-name><surname>Colin</surname><given-names>C</given-names></string-name>, <etal/></person-group>. <article-title>CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas</article-title>. <source>Neuro Oncol</source><year>2019</year>;<volume>21</volume>:<fpage>1519</fpage>–<lpage>28</lpage>.<pub-id pub-id-type="pmid">31832685</pub-id></mixed-citation>
              </ref>
              <ref id="bib37">
                <label>37.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shirahata</surname><given-names>M</given-names></string-name>, <string-name><surname>Ono</surname><given-names>T</given-names></string-name>, <string-name><surname>Stichel</surname><given-names>D</given-names></string-name>, <string-name><surname>Schrimpf</surname><given-names>D</given-names></string-name>, <string-name><surname>Reuss</surname><given-names>DE</given-names></string-name>, <string-name><surname>Sahm</surname><given-names>F</given-names></string-name>, <etal/></person-group>. <article-title>Novel, improved grading system(s) for IDH-mutant astrocytic gliomas</article-title>. <source>Acta Neuropathol</source><year>2018</year>;<volume>136</volume>:<fpage>153</fpage>–<lpage>66</lpage>.<pub-id pub-id-type="pmid">29687258</pub-id></mixed-citation>
              </ref>
              <ref id="bib38">
                <label>38.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mellinghoff</surname><given-names>I</given-names></string-name>, <string-name><surname>van den Bent</surname><given-names>M</given-names></string-name>, <string-name><surname>Clarke</surname><given-names>J</given-names></string-name>, <string-name><surname>Maher</surname><given-names>E</given-names></string-name>, <string-name><surname>Peters</surname><given-names>K</given-names></string-name>, <string-name><surname>Touat</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>RTID-05. Indigo: a global, randomized, double-blind, Phase 3 study of vorasidenib (AG-881) vs placebo in patients with residual/recurrent grade II glioma with an isocitrate dehydrogenase 1/2 (IDH1/2) mutation</article-title>. <source>Neuro Oncol</source><year>2020</year>;<volume>22</volume>:<fpage>ii194</fpage>.</mixed-citation>
              </ref>
              <ref id="bib39">
                <label>39.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schaff</surname><given-names>LR</given-names></string-name>, <string-name><surname>Kushnirsky</surname><given-names>M</given-names></string-name>, <string-name><surname>Lin</surname><given-names>AL</given-names></string-name>, <string-name><surname>Nandakumar</surname><given-names>S</given-names></string-name>, <string-name><surname>Grommes</surname><given-names>C</given-names></string-name>, <string-name><surname>Miller</surname><given-names>AM</given-names></string-name>, <etal/></person-group>. <article-title>Combination olaparib and temozolomide for the treatment of glioma: a retrospective case series</article-title>. <source>Neurology</source><year>2022</year>;<volume>99</volume>:<fpage>750</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="pmid">35948444</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
